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1. Introduction 
1.1 Signal transduction 
To ensure proper function of tissues and organs within an organism, cells must be able to 
respond to signals, not only from their local environment but also from external sources 
(Cooper, 2013). The transfer of these signals from external sources to the cell interior leads to 
triggering of a signal-specific cellular response that is referred to as signal transduction. In 
general, an extracellular signal activates different signal transduction pathways with widely 
varied mechanisms. However, the activation of these signal transduction pathways rely on 
cell surface receptors that are able to receive or identify external signals. These cell surface 
receptors are in turn activated by extracellular messengers (known as first messengers) such 
as light, heat, peptides, nucleotides and amino acids (Erin et al., 2013). The receptor 
activation by these first messengers subsequently activates intracellular signaling cascades 
that ultimately activate intracellular signaling molecules (known as second messengers) 
(Alberts et al., 2012) including cyclic nucleotides like cyclic adenosine monophosphate 
(cAMP), cyclic guanosine monophosphate (cGMP) and lipids like Phosphatidylinositol 
bisphosphate (PIP2) and also ions like Ca2+ (Scott et al., 2000). Intracellular signal 
transduction pathways are regulated by four important receptors, i) G protein coupled 
receptors ii) ligand-gated ion channel receptors iii) transcription factor receptors iv) enzyme-
linked receptors (Scott et al., 2000; Gomperts et al., 2002). Since the focus of this work was 
on GPCRs, the detail descriptions about GPCRs are discussed below. 
1.1.1 G protein coupled receptors (GPCRs) 
GPCRs are also known as 7-TM (trans membrane) receptors. In signal transduction, GPCRs 
represent a major group of cell surface receptors (Jastrzebska et al., 2006; Fredriksson et al., 
2003; Menzaghi et al., 2002). The human genome encodes more than 1,000 GPCRs, which 
constitutes approximately 2% of the entire human genome (Jiang et al., 2006). The GPCRs 
are implicated in a wide variety of diseases thus making these GPCRs as an important drug 
target for in the pharmaceutical industry and all clinical areas (Vassilatis et al., 2003). 
A wide variety of ligands binds to and activates GPCRs, including hormones and 
neurotransmitters leading to diverse biological responses such as neurotransmission, cellular 
metabolism, cellular differentiation, immune responses and so on ((Pierce et al., 2002; Jacoby 
et al., 2006).  
                                                                                                                             
Introduction 
 
 2  
 
GPCRs are composed of a single peptide, usually 300-500 but also up to 1400 amino acids. 
The superfamily of GPCRs shares the similar architecture of 7TM-α helices, and this consists 
of an extracellular amino-terminal and an intracellular carboxy-terminal. Based on sequence 
homology and functional similarities, GPCRs can be further divided into five major classes: 
i) glutamate receptors ii) rhodopsin receptors iii) adhesion receptors iv) frizzled receptors v) 
secretin receptors. However, the amino acid sequence similarities between these families are 
less than 20% (Lagerström et al., 2008).  
1.1.2 General mechanism of signal transduction through GPCRs 
When ligand or agonist binds to GPCR, the receptor is activated. Upon receptor activation, 
GTP replaces GDP on the α subunit of the G protein. Upon exchange of GDP for GTP, a 
conformational change takes place in GPCRs, this leads to dissociation of Gβγ from Gα 
(Fig.1). The dissociated subunits can activate distinct downstream effector proteins, resulting 
in a considerable amplification of the signal (Roberts et al., 2004) (Fig.2). Different variety of 
effector molecules including adenylyl cyclase (AC), phospholipase C (PLC), protein kinases, 
potassium and calcium channels are regulated by Gα. On the other hand variety of effectors 
such as adenylyl cyclase, phospholipase C-β (PLC-β), phosphoinositide 3-kinase (PI3-K) and 
β-adrenergic receptor kinases are regulated by Gβγ. Regulation of these effectors ultimately 
lead to production of second messengers, such as cAMP (Watts et al., 2005), cGMP, Ca2+ 
(Landry et al., 2006) and Inositol trisphosphate (IP3) (Ohno-Shosaku et al., 2005), and 
thereby control many biological and physiological responses such as cellular immune 
responses and neuronal transmission (Roberts et al., 2004). 
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Figure.1. Model for signal transduction by activation/inactivation of heterotrimeric G proteins 
through GPCR. In the inactive state, the Gα subunit is associated with GDP the GDP is bound to Gα 
(Gα-GDP). Upon receptor activation with agonist, the receptor undergoes a conformational change 
and acts as a guanine nucleotide exchange factor (GEF) for the α subunit, stimulating the exchange of 
GDP for GTP. In active state, the GTP is bound to Gα (Gα-GTP). Upon binding of GTP, the 
Gα subunit dissociates from the Gβγ dimmer and these proteins are released from the receptor. 
Dissociated Gα and Gβγ subunits then interact with a variety of effectors respectively to further 
transmit the signals and initiate unique intracellular signaling responses. Upon termination of the 
signal, the Gα-GTPase activity hydrolyzes the bound GTP (Gα-GTP) to GDP and Pi and inactivates 
the G protein complex by re-associating Gα with Gβγ. In this state GDP is again bound to Gα (Gα-
GDP) in G protein complex. RGS proteins can accelerate the deactivation by enhancing the GTPase 
activity. Adapted and modified from (Worzfeld et al., 2008). 
Some second messengers such as cAMP, cGMP, and IP3 are water soluble and can diffuse to 
some extent into the cytoplasm; whereas other second messengers such as DAG and 
phosphatidylinositol-3,4,5-trisphosphate (PIP3) are water insoluble, which are membrane-
associated lipids and diffuse in the plasma membrane (Rhee, 2001).  
G proteins are important signal transducing molecules in cells and they transmit signals from 
outside the cell to the cell interior. G proteins are activated by GPCRs and inactivated by Gα-
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GTP accelerating proteins (GAPs) such as RGS (regulators of G protein signaling) proteins. 
G proteins are composed by three distinct subunits α-, β- and γ-, where β- and  γ- subunits 
form an undissociable complex and represent a functional unit. Based on their G protein 
coupling preference, GPCRs can be broadly sub-classified into Gs-, Gi/o-, Gq/11- and 
G12/13-coupled receptors (Pierce et al., 2002). In this work Gαi- and Gαs- coupled receptors 
were used to study receptor-mediated changes in cAMP. Some of these receptors are briefly 
discussed below. 
1.1.2.1 M2-muscarinic receptor (M2-R)  
The muscarinic receptors are a subfamily of rhodopsin-like G protein coupled receptors. 
Muscarinic receptors are classified into five subtypes (M1-5). Based on their coupling to the G 
proteins, the muscarinic receptor family is further categorized into two classes. M2 and M4 
receptors couple predominantly to PTX-sensitive Gi proteins leading to inhibition AC and 
thus decreasing intracellular cAMP levels which results in reduced PKA activity. M1, M3, and 
M5 receptors preferentially couple to Gq proteins to activate phospholipase C (PLC). 
Activation of Gαq leads to an activation of phospholipase C-β (PLC-β), which then triggers 
the breakdown of phosphatidyinositol-4,5-bisphosphate (PIP2) to the second messengers 
inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). These receptors regulate primary 
functions of the central and peripheral nervous system (Gomeza et al., 2001). The M2-R is 
highly expressed in the heart and it is the most important subtype in cardiac tissues, where it 
induces negative chronotropic, dromotropic and inotropic effects (Hulme et al., 1990; 
Caulfield et al., 1993). M2-receptor knockout mice show a decrease in smooth muscle 
contraction and a decrease in body temperature (Wess et al., 2003). M2-receptor agonists 
including acetylcholine, carbachol, and pilocarpine are primarily used in ophthalmology to 
treat glaucoma (Zahn et al. 2002). These agonists bind to M2-R and regulate physiological 
responses such as adenylate cyclase inhibition and potassium channel activation. 
Acetylcholine is an important neurotransmitter in the autonomic nervous system (Lee & 
Higginbotham, 2005). The release of acetylcholine from post vagal parasympathetic neurons 
has inhibitory effects on heart rate and contractility (Murad et al., 1962; Löffelholz & 
Pappano 1985; Hartzell, 1988). These inhibitory effects can be attributed to inhibition of AC 
activity and cAMP production by a mechanism involving PTX-sensitive inhibitory G protein, 
Gi (Hazeki & Ui, 1981; Endoh et al., 1985). In addition to the direct inhibition of cAMP 
responses via inhibitory G proteins, a second level of cAMP regulation via Gi proteins has 
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been reported (Gilmour & Zips, 1985): In cardiac myocytes, it was observed that muscarinic 
receptor activation is facilitated β-adrenergic responses which immediately followed the 
termination of vagal stimulation or suspension of M2-receptor agonist (Hollenberg et al., 
1965; Levy, 1971; Burke & Calaresu, 1971; Gilmour & zips, 1985). This stimulatory 
response can explain physiological phenomena such as post-vagal tachycardia and 
arrhythmogenic mechanisms (Wang & Lipsus, 1996). However, the underlying mechanism 
was not clear so far for this stimulatory effect. This issue was addressed in the present study. 
In addition to Gαi, Gβγ activation via the M2 and M4 mAChR in the heart leads to activation 
of G protein coupled inward rectifying potassium channels (GIRKs) resulting in a decrease of 
the heart rate (Wickmann et al., 1999) 
1.1.2.2 β2-adrenoceptor (β2-AR) 
β2-adrenoceptor is a subtype of β-adrenoceptor. β2-adrenoceptor couple to Gs proteins leading 
to activation of adenylyl cyclase activity and thus increasing intracellular cAMP levels. The 
increase in cAMP leads to the stimulation of protein kinase A (PKA), which then alters 
cellular functions. The majority of β2-AR mediated signaling occurs via Gαs proteins and 
subsequent cAMP-dependent mechanisms. However, there is an evidence of other signaling 
schemes including Gαi activated MAPK pathway (Azzi et al., 2003). In this study, β2-AR is 
used to activate Gαs. 
β2-ARs are ubiquitously expressed in most tissues and are involved in a variety of 
physiologically relevant functions in the human body. β2-ARs are vastly distributed in muscle 
tissue including smooth muscle and striated muscle, where they relaxes myometrial smooth 
muscle in uterus. β2-ARs also regulates cell metabolism in skeletal muscle. β2-ARs are also 
expressed in the heart, where they increase (lesser extent compared to β1-ARs) cardiac 
contractility and heart rate (Uhln et al., 2010). The β2-ARs mediate vasodilation, 
glycogenolysis and lipolysis in the immune system. In the brain, β2-ARs are vastly distributed 
in different regions and regulate working memory and other brain functions (Wang et al., 
2010). In addition, β2 agonists induce bronchodilation in patients suffering from chronic 
obstructive pulmonary disease (COPD) and asthma (Celli & Macnee, 2004). Furthermore, β2 
agonists increase intraocular pressure in the eye. Based on the mechanism of actions, β2 
agonists are divided into two types, short acting and long acting agonists. In this the study 
short acting β2-receptor agonist Iso proterenol is used. 
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1.1.2.3 α2A-adrenoceptor (α2A-AR) 
Based on their primary structure, α2-AR is sub divided into three main subtypes (α2A-C). α2-
AR activate inhibitory G proteins (Gi) thereby inhibits adenylyl cyclases, resulting in reduced 
levels of intracellular cAMP and PKA activity.  
α2A-AR is highly expressed in both central nervous system and peripheral tissues such as 
kidney, lung, eye and skeletal muscle. α2A-AR is also involved in the synaptic brain function, 
where it controls the release of neurotransmitters (Hein et al., 1999). α2A-AR plays prominent 
roles in the cardiovascular system to regulate heart rate, blood pressure sympathetic nervous 
system and also regulate central nervous system functions. In addition, adrenoceptor agonist 
and antagonists are used clinically for many years in the treatment of different diseases 
including asthma, heart failure, hypertension and depression (Guyton et al., 2006). 
Furthermore, activation of α2-ARs causes platelet aggregation, and blood vessel constriction. 
In the spinal cord, α2-ARs have been shown to regulate nociceptive processing, blood 
pressure and spinal reflex (Yaksh et al., 1985). In pancreatic islet, activation of α2-AR leads 
to inhibition of insulin release from β cells (Nakaki et al., 1980). The α2A-adrenoceptor is 
activated by α2A-ARs agonists including clonidine, norepinephrine and epinephrine. The α2A-
AR agonist clonidine is an antihypertensive drug, lowers blood pressure and used for the 
treatment of hypertension (Engelman & Marsala et al., 2013). Epinephrine induces 
aggregation of human platelets. In this study α2A-AR agonist norepinephrine is used to 
activate α2A-adrenoceptor (Guyton et al., 2006).  
1.1.3 G protein mediated signal transduction 
G proteins are a family of proteins that are involved in transferring signals from GPCRs to a 
wide range of downstream effectors. G proteins are regulatory proteins that act as molecular 
switches in signal transduction pathways and they control a wide range of biological 
processes. The classical G proteins are subdivided into two main classes.  
1) High molecular weight G proteins or heterotrimeric G proteins 
2) Low molecular weight G proteins or Small GTPases 
Since the focus of this work was on signaling through heterotrimeric G proteins. These 
heterotrimeric G proteins are discussed below. 
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1.1.3.1 Heterotrimeric G proteins as signal mediators 
Heterotrimeric guanine nucleotide-binding proteins are also known as G proteins, which can 
be activated by GPCRs. The heterotrimeric G proteins are comprised of an α - subunit, a β - 
subunit and a γ - subunit. The β - and γ - subunits are tightly assembled into βγ - complexes 
and act as a functional unit. The Gα - subunit typically has a molecular weight of 36-56 kDa, 
Gβ - has a molecular weight of 35-36 kDa and Gγ - a molecular weight of 8-10 kDa 
(Nürnberg et al., 1995).  
 
Figure 2: GPCR signaling pathway. Stimulation of a G protein coupled receptor (GPCR) by a 
hormone results in a conformational change and the activation of G proteins. G proteins are 
heterotrimeric and upon stimulation, the Gαs subunit becomes activated by GDP/GTP exchange. Gαs 
subsequently dissociates from the regulatory Gβγ subunits (which can themselves activate other 
signaling pathways) and activates adenylyl cyclase (AC) to generate cyclic AMP (cAMP) from ATP. 
On the other hand Gαi proteins inhibit AC and cAMP production. cAMP can be hydrolyzed by 
phosphodiesterases (PDE). cAMP generation can then activate downstream effectors of the 
pathway, such as protein kinase A (PKA), Epac or cAMP gated ion channels (HCN) which can ellicit 
a diverse range of cellular processes.  
Upon ligand binding, GPCRs stimulate the α subunit of a heterotrimeric G protein to release 
GDP and to bind GTP in its place (Figure 1). In the GTP-bound form, Gα dissociates from 
Gβγ subunits, even though some data indicate that G protein activation may also lead to 
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subunit rearrangement rather than dissociation (Bünemann et al., 2003). However, the 
released and activated Gα-GTP and Gβγ further interact with their target downstream effector 
proteins, which then modulate a number of second messenger-generating pathways (Evanko 
et al., 2005; Wall et al., 1995; Forse, 2000). 
1.1.3.1.1 Gα-subtypes and functions 
Gα-subunits belong to a family of high molecular weight G proteins, having a molecular 
weight of 36-56 kDa. So far, 23 different Gα-subunits have been identified (McCudden et al., 
2005). Based on downstream signaling, Gα subunits can be further divided into 4 major 
classes (Gαs, Gαi/o, Gαq/11, and Gα12/13). The Gαs family includes Gαs and Gαolf. These 
subunits stimulate the activity of adenylyl cyclase (AC) and cause an increase in intracellular 
cAMP levels. Increased cAMP further activates PKA and Epac (Ross et al., 1977). Gαs is the 
only subunit known to directly activate AC (Sutherland et al., 1960; Rall, 1977). Gαs is 
widely expressed in most tissue types. However, Golf is expressed in olfactory neuroepithelial 
cells, brain, and pancreas. In addition to ACs, ion channels such as atrial voltage-gated 
sodium channels and dihydropyridine-sensitive calcium channels in skeletal muscle are also 
activated by Gαs (Sunahara et al., 1997).There are different bacterial toxins available to 
identify specific Gα-protein mediated signal transduction pathways, e.g., cholera toxin (CTX) 
and pertussis toxin (PTX). Cholera toxin is an enzyme released by Vibrio cholera. CTX 
catalyzes the transfer of ADP-ribose to Gαs, which inhibits its intrinsic GTPase activity and 
thus makes Gαs constitutively active, which causes persistent activation of adenylyl cyclase 
(Merritt et al., 1995). Gαs proteins are known to be activated by receptors such as β2-AR, 
Dopamine (D1-R), etc. 
PTX, the pathogenic toxin of Bordetella pertussis, induces ADP-ribosylation of Gα subunits 
of the Gi/o family except Gαz. Gαi thereby sequesters Gβγ-subunits, and fails to inhibit AC 
with a resulting increase in intracellular cAMP (Watts et al., 2005). The Gαi protein family is 
sensitive to PTX (Wu et al., 2005). The Gαi/o protein family consists of Gαi, Gαo, Gαz, Gαt 
and Ggust. The Gαi proteins are further divided into three main subtypes: Gαi1, Gαi2 and Gαi3. 
Almost all Gαi subunits inhibit adenylyl cyclase activity (ACs), thus promoting decreased 
intracellular cAMP. On the other hand, Gαi subunits activate phosphodiesterases (PDEs). 
Activation of Gαt leads to increased hydrolysis of cGMP, and activation of Ggust causes 
hydrolysis of cAMP.  
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Table 1: Classification and functional properties of Gα-subunit (Nürnberg, 2004) 
  
Family 
 
 Subtype 
Gαs(s),s(1)a 
 
Gαolf 
 
Tissue distribution 
ubiquitous 
 
olfactory epithelium, 
brain and pancreas 
    
Effectors                                                   Receptors(examples) 
↑AC                                                                  β1/β2-AR, D1-R  
                                                                           A2-R etc. 
↑AC                                                                  V2-R, odorant-R 
 
↓ AC1,5,6 (↑GIRKb, ↑PLCβb)                      α2-AR, M2/M4-R 
↓AC1,5,6 (↑GIRKb, ↑PLCβb,↑PI3Kb)        α2-AR, M2/M4-R 
↓AC1,5,6 (↑GIRKb, ↑PLCβb,↑PI3Kb?)       D2-R, A1-R, µ-OR 
↓AC? ↑VDCCb  ↓GIRKb ↓PLCβb)              LPA-R, SSTR 
↓cGMP-PDE                                                    Rhodopsin 
↑cGMP-PDE 
↑PDE 
↑AC1,AC 5(↑GIRKb, ↓VDCCb)                  AT II-R, ET-R 
 
↑PLC-β, Rho-GEF                                          M1/M3-R, V1-R 
↑PLC-β                                                            P2Y-R 
↑PLC-β  
↑PLC-β  
 
↑Rho-GEF,↓Btk, ↑Gap1m, cadherin          TxA2-R, LPA-R 
↑Rho-GEF, radixin 
 
      GS 
 
 
 
 
     Gi 
 
 
 
 
 
    Gq 
 
 
 
   G12 
Gαi1 
Gαi2 
Gαi3 
Gαo1,2,3c 
Gαt(r) 
Gαt(c) 
Gαgust 
Gαz 
 
Gαq                            
Gα11 
Gα14 
Gα15/16d 
 
Gα12 
Gα13 
mostly neurons 
ubiquitous 
mostly non-neuronal 
neurons 
retinal rods 
retinal cones 
taste cells 
neurons, endocrine, 
platelets 
ubiquitous                         
widely 
testis and 
hematopoietic 
cellshematopoietic 
cells and tissues 
 
ubiquitous 
ubiquitous 
 
                                                                                                                             
Introduction 
 
 10  
 
Table 1: Classification and functional properties of Gα-subunit.  Abbreviations for the text used 
in the table. α/β-AR= adrenergic receptors; V1/2= vasopressin receptors; D1/2= dopamine receptors; 
A1/2= adenosine receptors; M1-4-R= muscarinic receptors; SSTR= somatostatin receptors; µ-R= opioid 
receptors; TR= taste receptors; LPA-R= lysophosphatidicacid receptors; AT II-R= angiotensin II 
receptors; B2R= bradykinin receptors; P2y= purinergic receptors; TxA2-R= thromboxane receptors. a: 
(s) and (l) indicate short and long splice variants of Gαs. b: Regulation of effector presumably depends 
on direct interaction with Gβγ-dimers resulted from PTX-sensitive G protein. c: Gαo3 corresponds to 
deamidated Gαo1, representing 30% of total Gαo in brain. d: Gα15 and Gα16 are the mouse and human 
homologues of GNA15 gene product, respectively. ↑ Stimulation: ↓ inhibition; AC:  adenylyl cyclase, 
Btk: Bruton’s tyrosine kinase, cGMP-PDE: cGMP-phosphodiesterase, Gap1m: Ras GTPase-
activating protein, GIRK: G-protein-regulated inward rectifier K+-channel, PLC-β: phopholipase C-β, 
PI3K: phosphatidylinositol-3-kinase, Rho-GEF: guanine nucleotide exchange factor of the monomeric 
GTPaase Rho, VDCC: voltage-dependent Ca+-channel. Table was adapted and modified from Claus 
et al., 2000; Nürnberg, 2004. 
Gαi2 and Gαi3 proteins are very closely related. Adenylyl cyclases are stimulated directly by 
forskolin, and these stimulatory effects can be inhibited by Gαi2. Similar to Gαi2, Gαi3 also 
inhibits Gαs-stimulated AC activity (Obadiah et al., 1999). Other Gαi subunits such as Gαo 
and Gαz proteins also have an inhibitory effect on ACs. Furthermore, Gαi and Gαo are 
associated with Gβγ proteins which then regulate G protein-gated inwardly rectifying K+ 
(GIRK) channels. Gαt represents the Gα subunit of transducin which can be activated by 
visual receptor rhodopsin. On the other hand, Gαz is defined as the α subunit of gustducin. 
Gαi and Gαo proteins are predominantly expressed in the brain and heart, whereas Gαt and 
Gαz proteins have restricted tissue distribution but Gαt mediates the light response in retinas 
and Gαz proteins are involved in calcium mobilization (Liu et al., 2003). Gαi proteins are 
known to to be activated receptors such as M2-R, α2-ARs.  
The Gαq proteins are widely expressed. The Gαq protein family consists of Gαq, Gα11, Gα14, 
Gα15 and Gα16 subtypes. Gαq activate phospholipase C β (PLCβ), which generates second 
massagers such as diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (Ins(1,4,5)P3) (IP3). 
PLCβ, is an enzyme that catalyzes the hydrolysis of the phosphatidylinositol(4,5)-
bisphosphate (PI(4,5)P2) (Pavan et al., 2007; Rhee et al., 2000). Activated DAG stimulates 
protein kinase C (PKC), while the other second messenger IP3 triggers intracellular Ca2+ 
release by activation of receptors in the endoplasmic reticulum (ER) (Macrez-Lepretre et al., 
1997). Furthermore, Bruton’s tyrosine kinase (Btk) is also activated by Gαq both in vivo and 
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in vitro (Jing et al., 1998). The Gαq proteins are known to be activated by receptors such as 
muscarinic receptors (M1, M3, and M5-R) and Histamine receptors (H1-R). 
The last family of α subunits of G protein is Gα12. This family was not well characterized and 
also has relatively low sequence homology to the other heterotrimeric G proteins. The Gα12 
family is comprised of Gα12 and Gα13 (Strathmann et al., 1991). Gα12 proteins do not interact 
with ACs, but mainly activate the small G protein RhoA and its downstream effectors, which 
further affects cellular morphology including cell migration and invasion (Kristelly et al., 
2004). The Gα12 family is widely expressed and can induce different signaling pathways, 
which lead to activation of downstream effectors such as phospholipase C, phospholipase D 
or MAP kinase activation (Buhk et al., 1995; Gohla et al., 1999; Cvejic et al., 2000). It has 
been shown that Gα12/13 interacts with various other proteins like Btk, Ras GTPase-activating 
protein (Gap1m) and cadherin (Meigs et al., 2002). It has been also reported that extracellular 
signal-regulated activated kinase (ERK) is activated by G12/13 proteins. 
1.1.3.1.2 Gβγ-subtypes and functions 
Gβγ is an integral part of heterotrimeric G proteins. Gβγ
 
is a tightly complexed dimeric 
protein consisting of one Gβ- and one Gγ- subunit. Five Gβ (1-5) and twelve Gγ (1-12) 
subunits have been identified, which are expressed in humans. Gβ1-4 subunits share between 
80 and 90% amino acid sequence homology while the various Gγ- isoforms are much less 
conserved. Gβγ-dimers bind directly to GPCRs and enhance the binding of Gα-subunit to 
GPCRs. Gβγ proteins preferentially bind certain receptors or activate specific signaling 
pathways (McCudden et al., 2005). In addition, current evidence indicates that Gβγ is a 
possible therapeutic drug target in several diseases including heart failure, inflammation and 
leukemia (Lin et al., 2011; Runne et al., 2013; Williams et al., 2004).  
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Table 2:   Gβγ-mediated regulated effectors (Nürnberg, 2004) 
             Effector 
 
AC 1, AC 3, AC 5, AC 6,  AC 8 
AC 2a, AC 4a,AC 7a 
G protein regulated inward rectifier K+ channels (GIRK1-4) 
G-protein coupled receptor kinase (GRK2,3) 
Phosphatidylinositol-3-kinase-β-γ (PI3K-βb,-γ) 
Phospholipase C β1-3 
Phospholipase A 
RAF 1 Protein kinase 
Bruton’s-tyrosine kinase (Btk) 
Interleukin-2(IL-2)-inducible tyrosine kinase (TSK) 
T-type voltage dependent Ca2+-channels 
N-type calcium channels 
Tsk tyrosine kinase 
 
        Gβγ response 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2:   Gβγ-mediated regulated effectors. a: AC activity is super activated by Gβγ only if co-
activated by Gαs. b: Stimulation has been demonstrated under in vitro conditions only. P140Ras-GEF: 
guanine-nucleotide exchange factor of the Ras GTPase, Raf-1: member of the ras subfamily of serine 
protein kinases. ↑: stimulation, ↓: inhibition. Table was adopted and modified from Nürnberg, 
2004). 
The βγ-dimers do not only act as an anchor for Gα subunits to form the functional 
heterotrimer; they also possess regulatory functions. The most significant βγ-mediated 
regulation is on ACs. The effect of Gβγ on adenylyl cyclases is dependent on the type of 
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ACs. Some of them are activated, and others are inhibited by Gβγ
. 
 Of all mammalian ACs, 
only AC2 and AC7 isoforms are activated by Gβγ dimers. Upon activation of ACs, Gβγ 
stimulates cAMP via activated Gαs coupled receptors (Gao et al., 1991; Tang et al., 1991). 
On the other hand AC1, 3 and AC6 are inhibited by Gβγ dimers, thereby inhibiting cAMP 
production (Diel et al., 2006; Steiner et al., 2006). 
However, there are some contradictory reports about the Gβγ regulation of AC5. Some 
reports stated that AC5 was inhibited by Gβγ (Smrcka et al., 2008; Pavan et al., 2009) via 
activation of Gαs or activation of Gαi (Gao et al., 2007), while others reported that AC5 is 
conditionally stimulated by Gβγ (Sadana et al., 2009). Most of the Gβγ-effectors are 
regulated by Gαi-mediated subunits. 
In addition, the Gαi-mediated Gβγ dimer activates or inhibits many other effectors, including 
GIRK channel and N-type Ca2+ channels (Li et al, 1999). Furthermore, the G protein 
signaling effectors PLCβ and mitogen-activated protein kinase 1-3 (ERK1/2) are directly 
regulated by Gβγ, resulting in activation of PKC through IP3. PKC activation leads to 
stimulation of AC5 (Watson et al., 1994; Wu et al., 1993). Some classes of 
phosphatidylinositol 3-kinases such as PI3Kγ and PI3Kβ are directly activated by Gβγ-dimers 
(Maier et al., 2000). Mitogen-activated protein kinases are also activated by Gβγ
 
(Yamauchi 
et al., 1999).  
1.1.4. The main effector systems of GPCRs signaling 
Binding of the ligand to a GPCR activates heterotrimeric G proteins thereby activating 
specific isoforms (ACs), multiple second messengers (cAMP, cGMP and IP3), and second 
messenger-derived mediators (PKA, Epac, PKC, PI3K, PDE and Ca2+). 
1.1.4.1 Adenylyl cyclases (ACs)  
Adenylyl cyclases (ACs) are a family of enzymes which are regulated by GPCRs. ACs are 
important effectors for GPCRs, and are mainly responsible for cAMP synthesis. These 
enzymes play an important role in various cellular signal transduction processes, including 
cardiac contraction, smooth muscle relaxation and hormone secretion (Seamon et al., 1981; 
Coppe et al., 1978). In mammals, AC isozymes are central and important components of 
signal transduction pathways and these isozymes are encoded by at least ten independent 
genes (AC 1-10). Most of the AC isoforms are expressed at a limited number in tissues and 
are highly expressed in brain.  AC2, 3, 4, 5, 6 and AC8 are highly expressed in heart 
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(Feinstein et al., 1991; Bakalyar et al., 1990; Gao et al., 1991; Ishikawa et al., 1992; 
Yoshimura et al., 1992), whereas AC1 is expressed only in adrenal gland (Krupinski et al., 
1989) and AC7 is expressed in platelets (Krupinski et al., 1992). AC10 is expressed in testis 
(Buck et al., 1999). Among the ten AC isoforms, nine of them are membrane-bound, and 
these are closely related. The type 10AC isoform encodes a soluble isoform also referred as 
sAC (Gancedo et al., 2013). The nine membrane-bound AC isoforms are divided into five 
distinct categories based on their amino acid sequence similarity and regulatory properties. 
Group one consists of Ca2+/CaM-stimulated AC forms such as AC1, 3 and AC8; group two 
consists of Gβγ-stimulated AC isoforms such as AC2, 4 and 7; group three consists of 
Gi/Ca2+- inhibited AC isoforms including AC5 and AC6. Group four is the most divergent of 
the membrane-bound family and consists of forskolin-insensitive AC9 (Sosunov et al., 2001). 
AC10 isoform is found in cyanobacteria and also in mammalian cells (Fraser et al., 2005). 
Adenylyl cyclases are also regulated by free metal ions, P-site inhibitors and protein 
phosphorylation (Cooper, 2003). 
1.1.4.1.1 Adenylyl cyclase structure 
Adenylyl cyclases are large integral membrane glycoproteins having molecular weights of 
approximately 119 to 175 kDa. All nine mammalian transmembrane ACs share a common 
structure that consists of two cytoplasmic domains (C1 and C2) and two transmembrane 
domains (M1 and M2) each containing six membrane-spanning α- helices. The C1 and C2 
regions can be subdivided further into catalytic domains C1a and C1b and regulatory 
domains C2a and C2b. The catalytic subdomains C1a and C1b are most conserved and highly 
homologous to each other to form a functional unit. The C1 and C2 domains have 230 amino 
acid regions (Tang et al., 1991; Linder et al., 2006).  The C1a
 
and C2b regions resemble each 
other in each adenylyl cyclase (roughly 50% similar and 25% identical) (Tang et al., 1995). 
The C1a and C2a domains contribute to ATP binding. Membrane bound AC isoforms are 
regulated by G protein Gα- and Gβγ- subunits, forskolin, substrate inhibitors and P-site 
inhibitors (Cooper, 2003).  
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Table 3: Regulation of mammalian adenylyl cyclases (Hanoune et al., 2001) 
AC isoformsa Gαs Gαi Gβγ Forskolin Ca2+/CaM Protein 
Kinases 
Putative 
function 
 AC1 
 
 
 ↑ ↓Ca2+/CaM-
stimulated 
 ↓    ↑     ↑ ↑PKC(week) 
↓CaM kinase   
IV 
Learning 
memory,syn
aptic 
plasicity 
AC2  ↑   ↑   ↑  ↑PKC  
AC3  ↑     ↓  ↓   ↑ ↑ (in vitro) ↑PKC olfaction 
AC4  ↑   ↑   ↑  ↑PKC  
AC5  ↑    ↓    ↑     ↓ ↓PKA 
↑PKC 
 
AC6  ↑    ↓   ↑    ↓ ↓PKC, PKA  
AC7  ↑   ↑  ↑  ↓PKC Drug 
dependency 
AC8  ↑   ↓Ca2+   ↑    ↓ →PKC Learning 
memory 
AC9b  ↑   ↓    →               
↓calcinurin 
  
sACc → →  →   Sperm 
capacitation 
  
Table 3. Regulation of mammalian adenylyl cyclases. ↑ positive regulatory response; ↓ negative 
regulatory response; → no regulatory response. a: all isoforms except sAC inhibited by P-site 
inhibitors. b: inhibited by calcineurin. c: stimulated by bicarbonate. Adapted and modified from 
(Hanoune et al., 2001; Sunahara et al
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The full length sAC molecular weight is approximately 187 kDa. The isoform contains 
tandem catalytic C1 and C2 domains (Buck et al., 1999). The catalytic core is highly similar 
to that of transmembrane ACs. The sAC is stimulated by calcium and bicarbonate. 
Importantly, sAC is not known to be regulated by heterotrimeric G proteins (Chen et al., 
2000; Jaiswal et al., 2003). 
1.1.4.2 Regulation of adenylyl cyclases  
1.1.4.2.1 Regulation of adenylyl cyclases by free metal ions. 
ACs requires the binding of metal ions for catalytic activity (Dessauer et al., 1997). Some of 
the mammalian adenylyl cyclases are activated by free metal ions, including magnesium 
(Mg2+). Previously it was reported that AC5 and AC6 are physiologically inhibited by free 
Ca2+ (Scholich et al., 1997). However, the precise pharmacological contribution of 
manganese (Mg2+) in comparison to Mn2+ on AC is still unknown. 
1.1.4.2.2 Regulation of adenylyl cyclases by P-site inhibitors 
Most of the P-site inhibitors are monophosphates and represent physilogicol regulators of 
ACs. P-site inhibitors are analogs of AMP. The AMP directly binds to an inhibitory site on 
adenylate cyclase. P-site inhibitors such as deoxy-adenosine phosphate, adenine and AMP 
which inhibit AC activity. Recently it was reported that AMP was accumulated by metformin 
therby inhibits adenylyl cyclases (Madiraju et al., 2014). Metformin is an antidiabetic drug 
which is known to activate AMP activated protein kinase (AMPK). Previously it was 
reported that AC1, 3, 5, 7 and 8 are inhibited by P-site inhibitors such as adenine and 9-
(tetrhydro-2-furyl)-adenine, and there is no effect on other ACs (Johnson et al., 1997; 
Sunahara et al., 2002) 
1.1.4.2.3 Regulation of adenylyl cyclases by forskolin 
Forskolin is a cAMP activator and potentially activates all isoforms of mammalian 
membrane-bound ACs except AC 9 and sAC because of a Ser → Ala and a Leu → Tyr 
change in the binding pocket (Permont et al., 1996; Iyengar, 1993). Forskolin binds to the C1 
and C2 heterodimers and then activates AC (Tesmer et al., 1997). The interaction between 
AC and forskolin is predominantly by hydrophobic interactions and hydrogen bonds. The 
stimulation of cAMP-production by forskolin is likely to involve direct activation of adenylyl 
cyclase and facilitation and/or enhancement of receptor-mediated activation of AC. 
Stimulation by forskolin directly activates AC2, AC4, AC5, AC6 and AC7 with Gαs-
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mediated co-activation whereas, stimulation by forskolin activates AC1, AC3, and AC7 in 
cooperation with Ca2+-CaM (Tang et al., 1991; Insel et al., 2003). 
1.1.4.2.4 Regulation of adenylyl cyclases by Gα-subunits 
The mammalian AC activation occurs primarily through receptors coupled to the stimulatory 
G protein Gαs. All mammalian ACs (except AC10) are predominantly activated by GTP-Gαs. 
In addition to Gαs, Gαolf also stimulates AC (Jones et al., 1989). Crystallographic studies 
suggest that the interaction between Gαs and AC occurs through an α-helix that is highly 
mobile throughout the GTPase cycle of G proteins (Feldmann et al., 2002). The primary 
binding site for Gαs on AC is located on the C2 domain where it is formed by the α2’ and α3’ 
helices. The N-terminal portion of the catalytic domain C1 also contributes to Gαs binding 
(Tesmer et al., 1997).  
The inhibitory G protein family Gαi1, Gαi2, Gαi3, Gαz and Gαo selectively inhibit AC5 and 
AC6 (Taussig et al., 1994). However, Gαi does not compete with Gαs for the binding to the 
enzymes because the forskolin-stimulated activity is also inhibited (Wittpoth et al., 1999). 
Instead, structural modeling and mutagenesis experiments suggest a binding site for Gαi 
which is located in the crevice formed by α2 and α3 of C1, symmetrically opposite of the 
binding site of Gαs (Dessauer et al., 1998). In addition, the N-terminus of AC5 directly 
interacts with the C1 domain which has been implecation in the Gαi-mediated inhibition as 
well Gαs-mediated activation of AC5. Furthermore, the calmodulin-activated AC1 is 
inhibited by Gαi proteins. However, forskolin-stimulated AC1 is only partially inhibited by 
Gαi (Taussig et al., 1994). Furthermore, Gαo inhibits AC1 and AC8, although it is not as 
potent as other Gαi-subunits on AC5 and AC6 (Evanko et al., 2005). However, all other ACs 
are not sensitive to Gαi. 
1.1.4.2.5 Regulation of adenylyl cyclases by Gβγ-dimers 
Adenylyl cyclases are conditionally regulated by heterotrimeric G protein βγ-subunits. Gβγ-
subunits may show stimulatory effects on ACs, as in the case of AC2, AC4 and AC7, or 
inhibitory effects on ACs, as in the case of AC1, AC3, and AC8. Gβγ potently stimulates the 
AC activity of AC2, AC4, and AC7 but only in the presence of Gαs, suggesting that Gβγ 
enhances the capacity of Gαs to activate AC (Sunahara et al., 2002). In the C2 domain, amino 
acids 956 to 982 of AC2 have been mapped as the interaction site for Gβγ-subunits and Gαs-
GDP. Despite the high degree of sequence conservation among AC catalytic domains, this 
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sequence is not found in other AC isoforms not modulated by Gβγ. However, when Gβγ is 
released upon activation of Gαs coupled receptors, Gβγ neutralizes AC1 and AC8 stimulation 
by Gαs in some cell lines. However, the Gβγ-dimers are negative regulators of AC1 and AC8 
and can significantly inhibit effects of forskolin, Gαs and Ca2+/CaM on AC activity. The AC2 
family is stimulated conditionally by Gβγ. Gβγ potentiates Gαs-stimulated activity of AC4 
and AC7 by up to 5- to 10-fold (Bayewitch et al., 1998). However, this activity was observed 
only in the presence of Gαs, and there is no AC potentiating effect of Gβγ alone (Tang et al., 
1991; Tausig et al., 1995; Sadana et al., 2009). In addition, it has been reported previously 
that Gβγ
 
overexpression has a tendency to lower cAMP levels in cells expressing AC5 or 6 
(Bayewitch ML et al., 1998).  
1.1.4.2.6 Regulation of adenylyl cyclases by Ca2+/Calmodulin 
Ca2+/CaM are key regulators of group I ACs. Ca2+/CaM activate isoforms of AC1 and AC8. 
The binding sites for calmodulin have been identified in the C1b of AC1 and C2b of AC8. 
Calmodulin conditionally stimulates AC3 via calcium-dependent calmodulin kinase II and 
calcineurin/PP2B (Tang et al., 1991). However, this AC3 stimulation occurs only in the 
presence of Gαs or forskolin (Choi et al., 1992). Furthermore, the Ca2+/CaM-stimulated 
phosphoprotein-phosphatase calcineurin has an inhibitory effect on AC9 via an unknown 
protein kinase (Paterson et al., 2000). In addition, almost all AC isoforms are inhibited by 
non-physiological (high) concentrations (millimolar) of Ca2+ whereas (micromolar) Ca2+ 
concentrations inhibit AC5 and AC6 enzyme activity (Baker et al., 1998; Cali et al., 1994). In 
addition, CaM kinase 2 inhibited AC3 by phosphorylating it at Ser-1076 (Weij et al., 1996).  
1.1.4.2.7 Regulation of adenylyl cyclases by protein kinases and other proteins 
There are different protein kinases and proteins which directly regulate ACs, including 
protein kinase A or C. Protein kinase A negatively regulates AC5 and 6 activities by 
phosphorylation of these isoforms (Iwami et al., 1995). On the other hand, PKC regulates 
ACs either by inhibition or stimulation. AC2 and AC5 are activated by PKC, whereas AC4 
and AC6 are inhibited by PKC. Interestingly, PKC has opposite effects on the Gαs-stimulated 
AC2 (enhanced by PKC) and AC4 (inhibited by PKC). The stimulatory effect of Gβγ on AC2 
and AC4 is lost by PKC phosphorylation (Kawabe et al., 1994). However, AC9 is inhibited 
by PKC (Cumbay et al., 2004). PIP3 (product of PI3-K) activated atypical PKC isoform 
(PKCζ) can also stimulate AC5/6 (Nguyen et al., 2005).  Additional kinases, such as tyrosine 
kinases indirectly stimulate AC5 activity by phosphorylation of Gαs (Poppleton et al., 1996). 
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Furthermore, AC3 is inhibited by CaM kinase II (Weij et al., 1996). Additionally, some other 
G proteins also regulate ACs (specifically AC3), including RGS proteins. However, a direct 
association between RGS proteins and AC3 has so far not been demonstrated. Furthermore, 
nitric oxide also may inhibit AC5 and AC6 (Hill et al., 2000). 
1.1.5 Cyclic nucleotide signaling 
The cyclic nucleotides (cAMP and cGMP) are identified as important intracellular signal 
transduction molecules, acting as second messengers between extracellular signal such as a 
hormone or neurotransmitter and the elicited intracellular response. Cyclic nucleotide 
signaling is a key regulator of many cellular processes such as cell migration, proliferation, 
growth and apoptosis. 
1.1.5.1 Cyclic adenosine monophosphate (cAMP) 
cAMP is a ubiquitous intracellular second messenger, which transmits signaling information 
from receptors to many different effector proteins within the cells. cAMP was first discovered 
in 1957 as a intracellular mediator of the glycogenolytic action of epinephrine and glucagon 
in the liver (Sutherland, 1960). Intracellular cAMP levels are not only regulated by AC but 
also cAMP specific phosphodiesterases (PDEs), which degrade intracellular cAMP (Omori, 
2007). cAMP can elicited a wide range of cellular processes including cell differentiation, 
proliferation, neurotransmission, and transcription (Houslay et al., 1997). The transduction of 
intracellular cAMP into a cellular response can be achieved by several cAMP effectors 
proteins (Beavo et al., 2002). 
1.1.5.2 cAMP effectors  
There are several different cAMP effectors in cAMP signal transduction, including cyclic-
dependent protein kinase (PKA), cAMP-dependent guanine nucleotide exchange factor 
(cAMP-GEFs) or exchange protein directly activated by cAMP (Epac) and cAMP nucleotide-
gated ion channels (CNG) such as hyperpolarized cyclic nucleotide gated channel (HCN). 
The detail description of these effectors discussed below.  
1.1.5.2.1 Protein kinase A (PKA) 
PKA is an important cAMP effector in GPCR signaling. The majority of cAMP downstream 
signaling effects are occurring through PKA (Tasken & Aandahl et al., 2004). cAMP 
activated PKA is one of the major mechanisms by which cellular events are controlled. PKA 
is a heterotetramer, which is composed by two catalytic (C) subunits and two regulatory (R) 
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subunits. Each subunit has multiple isoforms with 4 regulatory (RIα, RIβ RIIα and RIIβ) and 
3 catalytic (Cα, Cβ, Cγ) subunits. The catalytic subunit contains a domain that binds ATP and 
one which binds the regulatory subunit. The regulatory (R) subunit contains two domains, 
which binds cAMP. The catalytic subunits are bound to the regulatory subunit dimer and are 
inactive when cyclic AMP levels are low. The catalytic subunits are active when cAMP binds 
to the regulatory subunits, leading to an allosteric change in conformation. Then the free 
catalytic subunits are active and start to phosphorylate their targets. The PKA holoenzyme 
can be classified in to two types. Type I (RIα and RIβ dimers) and type II (RIIα and RIIβ 
dimers). Type 1 is soluble and located in the cytoplasm and more sensitive to cAMP than 
Type II. Type II is associated with sub-cellular structures, being anchored by scaffolding 
proteins called A-kinase anchoring proteins (AKAPs) (Michel et al., 2002). PKA 
phosphorylation activates Ca2+ channels, resulting an increase in intracellular [Ca2+] level and 
an increase in myocytes contraction in the heart. Furthermore, PKA can phosphorylate 
complex 1 of the respiratory chain of mitochondria, thereby regulates oxidative energy 
production (Papa et al., 2012). 
1.1.5.2.2 Exchange protein directly activated by cAMP (Epac) 
Apart from PKA, cyclic AMP also activates cAMP regulated guanine nucleotide exchange 
factor (cAMP-GEF). It is also called as Epac (Holz et al., 2006). Epac regulates vital 
processes, including cell proliferation, differentiation, calcium handling and neuronal 
signaling. There are two isoforms of Epac identified so far: Epac1 and Epac2. Epac1 is 
expressed ubiquitously, whereas Epac2 is predominantly expressed in the brain (Kawasaki et 
al., 1998; de rooji, 1998). Ras superfamily has small GTPases such as Rap1, and Rap2 and 
both are stimulated by cAMP activated Epac proteins. Both Epac1 and Epac2 share extensive 
sequence homology and both contain an N-terminal regulatory region and a C-terminal 
catalytic region. Epac2 has an additional N-terminal cyclic nucleotide-binding domain 
(CNB), the function of this extra domain is not clear. The C-terminal catalytic region of 
Epac2 consists of Ras association domain (RA) and a CDC25-homology domain. The N-
terminal regulatory region of Epac1 and Epac2 shares a Dishevelled-Eg1-10-Pleckstrin (DFP) 
domain followed by a CNB domain (Fig. 3) (de Rooji, 2000). 
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Figure 3: Domain structure of exchange protein directly activated by cAMP (Epac). The domain 
structure of Epac1 and Epac2 indicating a cyclic nucleotide binding domains (CNB) and a catalytic 
region with CDC25 homology domain (CDC25HD), which is responsible for the guanine nucleotide 
exchange activity. The DFP (Disheveled/Eg1-10/pleckstrin) (DEP) domain that is involved in 
membrane localization, the Ras exchange motif (REM) which stabilizes the catalytic helix of 
CDC25HD and Ras-association domain (RA). The figure was adopted and modified from (Johannes, 
2006). 
Epac modulates intracellular Ca2+ in the heart (Emily et al., 2009).  Epac proteins regulate a 
wide variety of cellular functions, such as cell adhesion, cell differentiation, proliferation, 
gene expression and apoptosis (Kiwmayer et al., 2005; Qiao, et al., 2002). Epac attributes to 
the secretion of insulin (Gloerich et al., 2010). Furthermore, neuronal functions including 
neuronal differentiation, neurite outgrowth, and axon regeneration are also regulated by Epac 
(Chistensen et al., 2003). Most leukocytes express the Epac1, which directly controls 
inflammation by regulating the immune response of leukocytes (Metrich et al., 2010). Epac1 
signaling regulates inflammatory responses of vascular endothelial cells (Sands et al., 2006). 
Furthermore, recent pieces of evidence indicated that Epac is being involved in renal diseases 
(Patschan et al., 2010).  
1.1.5.2.3 Hyperpolarization-activated cyclic-nucleotide-gated channel (HCN)  
Hyperpolarization-activated cyclic-nucleotide-modulated channels are cation channels that 
are directly activated by intracellular second messengers such as cAMP and cGMP. HCN 
channels are widely expressed in the heart and central nervous system (CNS). HCN channel 
family comprises four members (HCN1-4) (Kaupp et al., 2002). HCN channels are regulated 
by many neurotransmitters, including norepinephrine and ACh. For example, norepinephrine 
activates β-adrenergic receptors which increases levels of cAMP which activate HCN 
channels and leads to a positive chronotropy in the heart (Ludwig et al., 1998). Neuronal 
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excitability, dendritic integration of synaptic potentials and synaptic transmissions are also 
controlled by HCN channels. Some recent reports indicate that HCN channels may contribute 
to mechanisms of epilepsy and pain (Postea et al., 2011; Nobels et al., 2012).  
1.1.5.3 Cyclic guanosine monophosphate (cGMP) 
cGMP is also an important intracellular second messenger which mediates a wide variety of 
cellular processes. cGMP is generated by two important guanylyl cyclases (GCs), one is 
nitric oxide (NO)-sensitive soluble guanylyl cyclase (sGC) and the other one is natriuretic 
peptide (NPP)-activated plasma membrane-bound particulate guanylyl cyclase (PGC) 
(Waldman & Murad, 1988; Bryan et al., 2009). These two guanylyl cyclase isoforms are 
widely expressed in many cells and tissues (Bryan et al., 2009). The generation of cGMP 
further activates downstream signaling pathways such as cyclic guanosine monophosphate-
dependent kinases (PKGs), cGMP-gated cation channels and PDEs (Hofmann, 2005; 
Lohmann & Walter, 2005; Lincoln et al., 2006). PKG is positively regulated by cGMP. In 
addition, cGMP also regulates intracellular concentrations of cAMP by activating or 
inhibiting cAMP-specific PDEs. It has been reported that PDE3 and PDE1 are inhibited by 
cGMP. This prevents cAMP breakdown and thereby indirectly increases intracellular cAMP 
levels (Hofmann et al., 2000).  
1.1.5.4 Phosphodiesterases (PDEs) 
PDEs are a family of enzymes. The intracellular levels of second messengers such as cAMP 
and cGMP are regulated through degradation by PDEs. The diverse family of cyclic 
nucleotide PDEs are important regulators of signal transduction and they influence ion 
channel function, muscle contraction, learning and many other cellular responses. PDEs have 
been identified as important drug targets for treatment of several diseases, including heart 
failure, depression, asthma and inflammation (Conti et al., 2000; Torphy et al., 1998). Based 
on amino acid sequences, regulatory properties and catalytic characteristics, mammalian 
PDEs are so far grouped into eleven families (PDE1-11) (Thompson et al., 1979; Beavo et 
al., 1982). Some of these enzymes only hydrolyze cAMP (PDE4, PDE7 and PDE8) while 
others only hydrolyze cGMP (PDE5, PDE6 and PDE9) and the remaining PDEs show mixed 
specificity (PDE1, PDE3, PDE10 and PDE11). PDEs contain three functional domains: a 
conserved catalytic core, a N-terminal regulatory and a C-terminal domain. The N-terminal 
portions of PDEs are widely divergent and contain structural determinants that allow PDEs to 
respond specific regulatory (Martinez et al., 2002). This region contains additional binding 
domains for calmodulin in case of PDE1, for cyclic GMP in case of PDE2 as well as 
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phosphorylation sites for various protein kinases in cases of PDE1-5, and a transducin 
binding domain in case of PDE6 (Card et al., 2004; Jeon et al., 2005). Intracellular 
cAMP/cGMP levels are increasing upon PDE inhibition, which in turn regulates various 
physiological functions. Among 11 PDEs, PDE4 and PDE7 have a higher specificity for 
activation by cAMP than cGMP or Ca2+/calmodulin (Conti & Zin., 1998). In addition, PDE4 
is particularly sensitive to inhibition by rolipram. PDE4 inhibition results in accumulation of 
intracellular cAMP, and thereby downstream activation of PKA, which subsequently 
phosphorylates transcription factor cAMP-response element binding protein (CREB) 
(Wachtel, 1982). PDE4 is expressed in many but not all cell types, and it has been considered 
as suitable drug target for the treatment of respiratory disease such as asthma and chronic 
obstructive pulmonary disease (COPD) (Rabe et al., 2011). PDE3 is also able to hydrolyze 
cGMP with high affinities (Degermann et al., 1997). 
The cGMP-dependent PDEs regulate cAMP response in several cell types. In vascular 
smooth muscle cells (VSMCs), nitric oxide (NO) activates PKA signaling through cAMP-
dependent inhibition of PDE3 leads to elevations of cAMP (Manganiello et al., 1995; Beavo, 
1995). However, in cardiac myocytes, cGMP-dependent PDEs also regulate cAMP 
responses. It has been reported that cGMP-inhibits PDE3, increases cAMP in human atrial 
myocytes (Kiristein et al., 1995).  
1.1.5.5 Protein kinase C (PKC) 
Protein kinase C (PKC) is a family of protein kinases which phosphorylate serine and 
threonine residues in many target proteins (Benjamin et al., 2000). PKC plays an important 
role in many cellular functions such as cell proliferation, differentiation and apoptosis (Maioli 
et al., 2006). 
PKC family can be divided into three main subtypes: PKC-α, PKC-β and PKC-γ. All these 
three subtypes are activated by DAG and calcium. Binding of ligand such as hormone or 
neurotransmitter to GPCR, activates heterotrimeric G protein Gαq/11 (Calpham & Neer, 
1997). Upon activation of G protein Gαq/11, PLC-β get activated and cleaves PI(4,5)P2 
resulting generation of second messengers such as InsP3 or IP3 and DAG. DAG stimulates the 
PKC together with elevated [Ca2+]. IP3 stimulates intercellular Ca2+ release from ER and 
thereby alters many cellular processes including cell proliferation, gene activation and cell 
death. On the other hand Gβγ subunit of G proteins also directly couples to PLC, PI3K and 
K+. It’s been reported previously that Gβγ directly stimulates PLC-β, and thereby activate 
PKC, which then stimulates AC5/6 in a Gs dependent manner (Calpham & Neer, 1997).  
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1.1.5.6 Phosphatidyl inositol phosphatases (PtdInsPs or PIPs)   
Phosphatidyl inositol phosphates (PtdIns) are a family of phospholipids in cell membranes. 
PtdInsPs interact with many different proteins through a common binding domain and 
triggers downstream signaling. There are mainly four species of PtdIns in D3 position: PI3P, 
PI(3,4)P2, PI(4,5)P2, PI(3,4,5)P3, which are present in cells (Fig. 4). PtdIns3P is found in 
lower eukaryotes, like yeasts, whereas PI(3,4)P2 and PI(3,4,5)P3  are found in almost all 
eukaryotic cells (Michell et al., 2007).  
 
 
Figure 4: Structure of selected phosphoinositides. A schematic of PtdIns and some of it’s 
phosphorylated derivatives. Black arrows indicate that kinase is involved; conversely, a white arrow 
indicates that phosphatase is involved. (Adapted from Hirsch et al., 2006). 
1.1.5.6.1 Phosphoinositide 3-kinases (PI3Ks) 
PI3Ks are lipid kinases that are activated by the binding of growth factors, insulin and 
cytokines to cell surface receptors and the subsequent activation of the GPCR or tyrosine 
kinase receptor. The activated PI3K catalyse the phosphorylation of phosphatidylinositol at 
the at the 3’ position of the inositol ring, producing secondary messenger lipids, which 
control cellular activities including cell growth and proliferation (Engelman et al., 2006). 
Signaling through PI3 kinase regulates glucose and lipid metabolism and also induce 
lipogenesis and glucose uptake/metabolism in both muscle and adipose tissues (Kahn, 1995). 
There are three classes of PI3 kinases: Class I PI3K, class II PI3K, and class III PI3K. Among 
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three classes of PI3Ks, class I PI3K is known as the best-characterized type so far. Based on 
sequence similarity, class I PI3Ks are further divided into two subgroups, Class IA and Class 
IB. Class IA PI3Ks are activated by stimulation of different receptors including tyrosine 
kinase receptor. Class IA PI3K are heterodimers, which contain a catalytic (p110α, p110β, 
and p110δ) and a regulatory subunit (P85α, p85β, p55α, p55γ, and p50α). P85α regulatory 
and p110α and p110β catalytic subunits are the most widely expressed subunits. There are 3 
isoforms in class IA including PI3Kα, PI3Kβ and PI3Kδ with the respective p110γ catalytic 
subunit bound to the p85 regulatory subunit. PI3Kα and PI3Kβ are ubiquitously expressed, 
while PI3Kδ is limited but preferentially found in leukocytes, and PI3Kγ has been found 
recently in the cardiovascular system (Hirsch et al., 2006). Among all classes of PI3 kinases, 
only class IB PI3K is directly activated by GPCR via heterotrimeric G proteins. The class IB 
PI3Kγ is composed of p101 regulatory subunit and p110γ catalytic subunit.  The p101 
regulatory subunit responds to specific GPCR-associated G protein, βγ subunits and a γ P110 
(p110γ) catalytic subunit, thus activating the class IB PI3K and production of PI(3,4,5)P3 
(Walker et al., 1999). In addition, the X-ray crystallographic studies reveled that PI3K 
inhibitors such as wortmannin and LY294002 and the broad-spectrum protein kinase 
staurosporine are bound to p110γ subunit (Suire et al., 2005). These inhibitors effectively 
inhibit or block the enzymatic activity of all PI3K via Gβγ subunits (Kurosu et al., 1997; 
Maier et al., 1999; Stephens et al., 1997; Walker et al., 1999).  
1.1.5.6.2 Regulation of PI(3,4,5)P3 and PI(3,4)P2 phosphatases 
All class I PI3Ks preferentially phosphorylates PI(4,5)P2, generating PI(3,4,5)P3 and 
PI(3,4)P2. In these two phospholipids, PIP3 is an important signaling molecule and act as 
second messenger. Activation of PIP3 further triggering the activation of its downstream 
effectors such as PDK1 (phosphoinositide-dependent kinase-1), Akt/ Protein kinase B (PKB) 
and mTOR (mechanistic target of rapamycin) through plekstrin-homology (PH) (Wymann et 
al, 2005). These effectors facilitate cellular processes.  
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Figure 5: The PI3K/PIP3/Akt pathway. Binding of growth factors to G protein coupled receptors, 
recruits and activates PI3K. Activated PI3K phosphorylates PI(4,5)P2 to PI(3,4,5)P3, which leads to 
phosphorylation of Akt by PDK1. Phosphorylated Akt is active on a wide range of substrates.  One of 
its most important targets is mTOR, which is involved in cell growth, proliferation and cell survival. 
SHIP is a phosphotase which catalyzes conversion of PIP3 to PI(3,4)P2, which also activates Akt, 
DAPP1 and TAPP1/2, and thus regulate pivotal cellular processes including cell proliferation and cell 
growth. PTEN is a tumor suppressor gene that negatively regulates the pathway by removing the 3-
phosphate from PIP3, thus converting it back to PI(4,5)P2. Further, PLCγ converts PI(4,5)P2 to IP3 and 
DAG (Cully et al., 2006).  
The activation of PIP3 is regulated by tumor suppressor protein phosphates and tensin 
homologue deleted on chromosome 10 (PTEN) (Li & Sun, 1997, Li, et al., 1997, Stock, et 
al., 1997), which dephosphorylates and thus negatively regulates PIP3-dependent signaling 
(Maehama & Dixon, 1998). In addition, PTEN dephosphorylates downstream effectors of 
PIP3, including PDK1 and Akt/PKB (Cantely & Neel, 1999). 
PI(3,4)P2 is another phospholipid and also acts as second messenger. PI(3,4)P2 is generated 
by dephosphorylation of PIP3 on the 5´ phosphate of the inositol ring by SHIP. PI (3,4)P2 
bind and activates PDK1, Btk (Bruton tyrosine kinase), Akt/PKB and tandem PH-domain-
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containing proteins (TAPP1/2) (Aman et al., 1998; Bolland et al., 1998; Cully et al., 2006). 
However, PI(3,4)P2 is also dephosphorylated by the phosphatase INPP4B on 5 prime position 
of the inositol ring (Kalesnikoff et al., 2003). 
SHIP (Src homology 2-containing inositol 5’ phosphatase) is a lipid phosphatase, which 
hydrolyzes at 5 prime position of inositol ring from inositol 1,2,4,5-tetraphosphate and PIP3 
and converts PI(3,4,5)P3 to PI(3,4)P2 (Damen et al., 1996; Lioubin et al., 1996).  
1.1.5.6.3 PI3K downstream effectors 
Generation of PI(3,4,5)P3 from PI(4,5)P2 by PI3K, further triggers several important 
downstream signaling mechanisms via specific lipid-binding domains such as PH domain 
containing proteins. Many, though not all PH domains containing proteins binds to PIs. One 
of the major downstream signaling events triggered by PI3K is the activation of members of 
the serine/threonine kinases such as PDK1 and PKB/Akt. Binding to PIP3 triggers the 
activation of PDK1, which can phosphorylate the threonine 308 of PIP3-bound PKB/Akt. 
Phosphorylation of Akt further activates the rictor-mTOR protein complex, which further 
phosphorylates its target substrates and regulates cellular responses including gene 
transcription and cell proliferation (Brazil et al., 2004). In addition, activation of PDK1 
phosphorylates and activates atypical PKC, PKC-ζ, resulting stimulation of AC5/6 (Dessauer 
et al., 2006; Romy et al., 2013).  However, a wide numbers of proteins (75 substrates have 
been described so far) are phosphorylated by PKB/Akt. Among, the best-characterized 
substrate is glycogen synthase kinase3 (GSK3). Furthermore, PH domain-containing tyrosine 
kinases including Tec and Btk are triggered by PI3K (Lindvall, 2002).  
1.2. Real-time FRET (Fluorescence or Förster resonance energy transfer) 
measurements.  
Förster resonance energy transfer (FRET) was first discovered by a German scientist, 
Theodor Förster in 1946. In recent years, FRET has become an extremely powerful tool for 
identifying molecular interactions between fluorescently labeled molecules use 
conformational changes of those in living cells. It can be used in a variety of molecular 
techniques including microscopy, flow cytometry and ELISA. FRET is a non-radiative 
transfer of energy between nearby fluorophores, these fluorophores often referred as acceptor 
and donor. FRET is basically dependent on the distance between acceptor and donor 
fluorophores. When the energy is transferred from the donor fluorophore to an acceptor 
fluorophore, the donor fluorescence is loose, whereas acceptor fluorescence is gained. The 
energy transfer can be monitored using any fluorescence microscope or fluorometer. 
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However, FRET does not occur, if the distance between two fluorophores exceeds 10 nm. In 
addition, there are three key conditions to allow the Föster mechanism are 
• The donor and acceptor molecules must be in close proximity to each other 
(approximately 1-10 nanometers).  
• The absorption spectrum of the acceptor must overlap with the emission spectrum of 
the donor. 
• The relative orientation of the dipole moment of donor and acceptor should be 
parallel. 
Förster showed that the efficiency of FRET (EFRET) depended on inverse sixth power of 
distance between the pair of molecule(r) 
                                               
                                        EFRET = 1/(1 + (/)	 
 
Where R0 is known as Forster distance, r is actual distance between pair. 
Before FRET experiments can be performed successfully, it is important to choose the right 
fluorescent pairs. The most commonly used FRET pair for FRET studies is cyan fluorescent 
protein (CFP) and yellow fluorescent protein (YFP) (Tsien, 1998). This CFP-YFP pair has 
strong spectral overlap, and this allow high resolution for FRET recordings. By genetic 
engineering, these FRET pair can be easily incorporated into proteins, which allows to 
measure GPCR signaling kinetics such as second messenger breeding, receptor G protein 
coupling, receptor activation and ligand binding in live cells (Ferrandon et al., 2009; 
Janetopoulos et al., 2001). 
There are three different methods for measuring FRET efficiency. 1, FRET acceptor 
photobleaching 2, Sensitized emission 3, FLIM-FRET. These methods are discussed briefly 
in sections below.  
1.2.1 FRET-acceptor Photo-bleaching (AB): For acceptor photobleaching, the FRET acceptor 
molecule of the FRET pair is bleached, the resulting donor fluorescence is unquenched after 
photobleaching of the acceptor. The difference of fluorescence intensity of the donor pre and 
post-photobleaching gives direct FRET efficiency. This method is suitable only for steady 
state experiments. 
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1.2.2 Sensitized Emission (SE): The second possibility is to measure FRET by sensitized 
emission, and it is one of the most used method for determining FRET dynamics. In this 
method, donor molecule is excited and measured in the acceptor channel. In our FRET 
experiments CFP- is excited, the CFP- and YFP-fluorescence were recorded simultaneously 
and the subsequent ratio of YFP-over CFP fluorescence was calculated. Before the 
occurrence of FRET, a strong CFP- and weak YFP- emission resulting in a low YFP/CFP 
ratio is observed. Upon the occurrence of FRET, a strong YFP- and a weak CFP- emissions 
resulting a high YFP/CFP ratio will be observed (Figure 6). This method is most frequently 
used for live cell experiments. 
In this study, the generation of cAMP in GPCR signaling pathway is investigated by 
sensitized emission method.  
            
Figure 6: FRET-changes during sensitized emission. The sketch indicates that FRET only occurs if 
the acceptor (YFP) is close enough to the donor (CFP). 
1.2.3 Fluorescence life time imaging: Fluorescence lifetime imaging is also known as 
FLIM. FLIM is more frequently used in FRET-based protein interaction methods. FLIM-
FRET measures the change in decay function of FRET donor. When energy is transferred 
from donor molecule to acceptor molecule, the lifetime of donor will decrease, this change in 
fluorescence lifetime of donor is used to calculate FRET efficiency. FLIM-based FRET 
measurement does not face problems like donor bleed-through or direct excitation of 
acceptor. However, there are some disadvantages of this method. This system is not suitable 
to measure faster imaging because the imaging system is slow and this system is somewhat 
destructive because the excitation energy is too strong result a photobleaching over time. 
1.3 Real-time cAMP measurements by FRET 
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To study real-time dynamics of cAMP signaling in living cells, a number of FRET-based 
biosensors have been developed in recent years including PKA-camps and Epac1-camps 
(Ponsioen et al., 2004; Nikolaev et al., 2004).  
                            
Figure 7: Structure of a single-chain cAMP FRET sensor (Epac1-camps). The Epac1-camps 
sensor reports intracellular levels of cAMP based on FRET between CFP and YFP. It consists of CFP 
and YFP fuses to a single cAMP-binding domain derived from Epac1 protein. In absence of cAMP, 
the two fluorophores are in close proximity, and strong FRET signal is observed. Upon cAMP binding 
to sensor, the distance between two fluorophores increases, leading to decrease in FRET. (Adapted 
and modified from Nikolaev et al., 2011) 
These sensors measure relative fluorescence of two fluorescent proteins used as donor and 
acceptor fluorophores, typically cyan (CFP) and yellow (YFP) fluorescent proteins. PKA 
based sensors have some limitations and also show slower kinetics. Therefore, in this study 
we used Epac based FRET biosensor to measure real-time cAMP levels.  
Epac1-camps biosensor is one of the most sensitive cAMP sensors to measure real-time 
cAMP levels in intact cells and cardiac myocytes. The standard FRET pair CFP and YFP as 
donor/acceptor are fused to a single cAMP binding domain of the Epac protein. This 
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biosensor displays faster activation of kinetics and high dynamic range compared to earlier 
cAMP FRET biosensors. 
In the inactive state, the cAMP sensor has a closed confirmation, where the two fluorophores 
(CFP- and YFP-) are in close proximity, result a high FRET is observed. When binding of 
cAMP to the sensor leads to conformational change results a decrease in FRET signal as 
reflected by a decrease in YFP- and increase in CFP- fluorescence and the distance between 
two fluorophores is increased, which indicates increasing cAMP concentrations. 
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2. Aim of the study 
The theoretical background of this work is originated from the previous findings that the 
cAMP rebound stimulation was observed after termination of Gi/o-stimulation in HEK293T 
cells expressing AC5 (Milde et al., 2013). Similar cAMP rebound stimulation was observed 
immediately following after termination of vagal stimulation or withdrawal of exposure to 
muscarinic receptor agonist ACh in cardiac myocytes (Burke & Calaresu, 1972; Gilmour & 
Zipes 1985). However, the underlying mechanism for these cAMP rebound stimulation was 
unclear. Therefore, we choose a FRET-based approach to investigate the possible 
mechanisms for muscarinic receptor-induced cAMP rebound stimulation. There were 
previous reports speculated that PTX-sensitive G protein/adenylate cyclase/cAMP pathway 
might be a possible mechanism for muscarinic receptor-induced cAMP rebound stimulation 
(Wang et al., 1995; Bett et al., 2001). Most reliable FRET-based cAMP biosensor (Epac1-
camps) was chosen to monitor real-time cAMP levels and by using heterologous expression 
system, we therefore intend to study possible involvement of G protein/adenylyl 
cyclase/cAMP-dependent pathway on muscarinic receptor-induced cAMP rebound 
stimulation in cardiac myocytes and other intact cells. However, the main aim of this research 
was to reveal possible mechanisms underlying the muscarinic receptor-induced cAMP 
rebound stimulation.           
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3. Materials and experimental procedures 
3.1 Materials 
3.1.1 List of manufactures and distributors 
Aldrich  Hamburg, Germany 
Applichem Darmstadt, Germany 
Applied Biosystems  Waltham, USA 
Biochrom Berlin, Germany 
Bio-Rad Laboratories  München, Germany 
Calbiochem-Novabiochem  Darmstadt, Germany 
Carl Roth Karlsruhe, Germany 
Carl Zesis  Oberkochen, Germany 
Cell signaling Technology Leiden, Netherlands 
Chem rock technologies  Lafayette, USA 
Chroma  Foothil Ranch, USA 
Hartenstein Würzburg, Germany 
Image J  Bethesda, USA 
Invitrogen  Darmstadt, Germany 
Life technologies  Darmstadt, Germany 
Merck Millipore  Darmstadt, Germany 
Milteny Biotec  Bergisch Gladbach, Germany 
Nikon  Tokyo, Japan 
Neuvitro Braunschweig, Germany 
Olympus  Tokyo, Japan 
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Origin Pro  Northampton, USA 
Paa  Cölbe, Germany 
Perkin Elmer  Waltham, USA 
Promega Mannheim, Germany 
Qiagen Hilden, Germany 
Roche  Mannheim, Germany 
Santa Cruz  Heidelberg, Germany 
Sarstedt Nürnbrecht, Germany 
Sigma-Aldrich  Steincheim, Germany 
Thermo scientific Karlsruche, Germany 
Tocris  Bristol, United Kingdom 
Visitech  Bristol, United Kingdom 
Visitron  Puchheim, Germany 
3.1.2 Reagents  
[3H]-clonidine hydrochloride Sigma-Aldrich 
Acetic acid Sigma-Aldrich 
Acetylcholine Sigma-Aldrich 
Adenosine 5’-triphosphate (ATP)  Sigma-Aldrich 
Agarose  Biochrom 
Alprenalol  Sigma-Aldrich 
AS1949490  Tocris 
Bovine serum albumin (BSA) Sigma-Aldrich 
Calcium chloride (CaCl2) Sigma-Aldrich 
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Cilostamide   Santa Cruz 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich 
Dopamine Sigma-Aldrich 
Ethanol Carl Roth 
Ethidium bromide (10mg/ml) Promega 
Ethylenediaminetetraacetic acid (EDTA) Applichem 
EDTA free tablet Roche 
Forskolin  Sigma-Aldrich 
Gallein  Tocris 
H-89 dihydrochloride hydrate,  Cell signal 
Isoproterenol Sigma-Aldrich 
KT5720 Santa Cruz 
Magnesium chloride (MgCl2) Sigma-Aldrich 
HEPES Sigma-Aldrich 
Norepinephrine Sigma-Aldrich 
Pertussis Toxin (PTX) Sigma-Aldrich 
Platelet derived growth factor BB (PDGF BB) Milteny Biotec 
PMA Santa Cruz 
Potasium chloride (KCl) Sigma-Aldrich 
Rolipram Santa Ccruz 
SH-5  Santa Cruz 
Sodium chloride (NaCl) Sigma-Aldrich 
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Sodium dihydrogen phosphate (NaH2PO4) Sigma-Aldrich 
Sodium dodecyl sulfate (SDS) Carl Roth 
Staurosporin Sigma-Aldrich 
TrIS-(hydroxymethyl)-aminomethane (Tris) Sigma-Aldrich 
TURBO DNAse Life technologies 
Tween Sigma-Aldrich 
Wortmannin Sigma-Aldrich 
Yohimbine hydrochloride Sigma-Aldrich 
β-Mercaptoethanol (β-ME) Sigma-Aldrich 
 
3.1.3 Plasmids 
The fallowing plasmids were either already published or available in the lab. 
Plasmid Species Origin  Vector/Resistance 
 Epac1-camps human Viacheslav O. Nikolaev 
(Nikolaev et al., J.Biol.Chem. 2004) 
pcDNA3/Amp+ 
HCN2-camps human (Nilolaev et al., Circ Res. 2004)  pcDNA3/Amp+ 
AKAR4 human (Depry et al., Mol Biosyst. 2011)  pcDNA3/Amp+ 
Eevee-PKC human (Komatsu et al., Mol Biol Cell. 
2011)  
 pcDNA3/Amp+ 
AKT-PH-YFP human Dominik Oliver  pcDNA3/kanamycine 
AC4 mouse Viacheslav O.Nikolaev  pcDNA3/Amp+ 
AC5 human Carmen W. Dessauer 
(Sadana et al., Mol pharm. 2009) 
 pcDNA3/Amp+ 
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AC6 human Viacheslav O. Nikolaev  pcDNA3/Amp+ 
Gαs rat (Hein et al., J.Biol.Chem. 2006) pcDNA3/Amp+ 
Gβ1-wt human (Bünemann et al., 
Proc.Natl.Acad.U.S.A. 2003) 
 pCMV/Amv+ 
Gγ2-wt bovine (Bünemann et al., 
Proc.Natl.Acad.U.S.A.2003) 
 pcDNA3/Amp+ 
α2A-AR mouse (Bünemann et al., Proc. Natl.Acad. 
U.S.A. 2003) 
 pcDNA3/Amp+ 
M2ACh-R human (Roseberry et al., Mol.Pharamcol. 
2001) 
 pGES/Amp+ 
D1-R human Obtained fromMissouri S&T cDNA 
Resource Center 
pcDNA3/Amp+ 
PcDNA3  Invitrogen pcDNA3/Amp+ 
AC5∆ 66-137 human (Sadana et al., Mol pharm. 2009) pcDNA3/Amp+ 
PTEN human Dominik Oliver pGES/Amp+ 
Gαi1 human Moritz  Bünemann pcDNA3/Amp+ 
Gαi2 rat Moritz  Bünemann pcDNA3/Amp+ 
Gαi3 rat Moritz  Bünemann pcDNA3/Amp+ 
PLCβ2 
 
human Moritz  Bünemann 
 
pcDNA3/Amp+ 
M3ACh-R human 
 
Obtained fromMissouri S&T cDNA 
Resource Center  
pcDNA3/Amp+ 
Gβ-Cer human 
 
(Frank et al, J. Biol. Chem. 2005) 
 
pcDNA3/Amp+ 
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Gq-YFP mouse 
 
(Hommers et al, J. Biol. Chem. 
2010) 
 
pcDNA3/Amp+ 
 
 
Table 4: Plasmids used during the study 
 
3.1.4 Kits used 
 
  Product Name                                                                      Company 
Plasmid Midi kit                                                                      Qiagen 
RNase free DNase kit                                                              Qiagen 
BCA protein assay kit                                                              Thermo scientific 
RNA extraction kit                                                                   Qiagen 
iScript cDNA synthesis kit                                                       Bio-Rad 
iTaqTM Universal SYBER Green Supermix                             Bio-Rad 
 
Table.5  Kits used during the study 
3.1.5 Cell culture, cell culture media and supplements 
Bacteriological culture plates  Sarstedt 
Cover slips Neuvitro  
Dulbecco’s modified eagle’s medium (DMEM) Biochrom 
Dulbecco’s phosphate buffered saline (PBS) Biochrom 
Fetal calf serum (FCS) Biochrom 
L-glutamine Biochrom 
Luria-Bertani (LB) medium Applichem 
Penciline/streptomycin Biochrom 
Trypsin/EDTA Biochrom 
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Poly-L-lysin hydrobromid Sigma-Aldrich 
Effectene Quiagen 
6-well cell culture plates Sarstedt 
Petridishes Hartenstein 
Eppendorf tubes (1.5ml) Sarstedt 
Pipettes Sarstedt 
3.1.6 Cells and Cardiac myocytes 
Human cervical cancer cells (HeLa)  Obtained from Prof. Dr. Robert   
Grosse, Germany 
  
   Human embryonic kidney cells, stables (HEK293T) European collection of animal cell 
cultures 
  
Mouse atrial cardiac myocytes  Obtained from Prof. Dr. 
Viacheslav O. Nikolaev, Germany   
3.1.7 Software’s 
The fallowing software was used for the assigned purpose: 
1. Exporting Data from samples 
• Visitron software (from fluroscence microscopy) 
• Visitech software (from confocal microscopy) 
2. Data analysis and statistics 
• Microsoft Excel 2007 or newer 
• GraphPad Prism 5 
• Origin Labs Origin Pro 9 
3. Image analysis and modification 
• Image J 1.46r (http://imagej.nih.gov/ij/) 
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• Corel Photo-Paint X4 
4. Figure optimization  
• CorelDraw X4 
3.1.8 Microscopes 
The following microscopes were used in our study 
• Fluroscence Microscope (Zesis) 
• Confocal Microscope (Olympus) 
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3.2 Experimental procedure 
3.2.1 Molecular biological methods 
3.2.1.1 Generation of electro competent cells (E coli) 
A stock of bacterial cells were streaked onto an LB plates and grown overnight. Next day a 
single colony was selected for the starter culture and inoculated into 200ml of LB medium. 
Cells were allowed to grow at 37oC with shaking at 250-300 rpm, until density reached OD600 
of 0.3-0.6. 200ml of LB culture medium was splitted into four 50ml tubes. The cells were 
then centrifuged at 5000 rpm for 10min at 4oC. Supernatant was removed, and pellets were 
resuspended into 25ml ice-cold TSB. Tubes were incubated for 2-3hrs on ice. Aliquots 
(300µl in 1.5ml tubes) were frozen in liquid nitrogen and stored at -80oC.  
3.2.1.2 Transformation of E. coli 
The aliquot frozen cells were taken from liquid nitrogen and transfer into a 37oC heat block. 
100µL competent cells were added in 20µl of 5X KCM-buffer and 80µl of water. 2µl of 
DNA was added into the buffer mixture and incubated for 20min on ice and then incubated 
for 10min at room temperature (RT). 1ml of LB-broth was added to the buffer mixture and 
incubated for 50min shaking at 37oC. 60-100µL of the mixture was plated on ampicilin or 
neomycin contained LB-agar and incubated overnight.  
3.2.1.3 Amplification and plasmid preparation 
Medium-scale plasmid preparations were carried out according to Qiagen’s manufactures 
Plasmid Midi kit with 100ml of bacterial suspension grown overnight.  
Yield and purity of plasmid DNA were determined by using a Nano Photometer (Implen 
GmbH, München, Germany) with 1 cm path length, and the DNA concentration was 
calculated according to Beer’s law. Plasmid DNA solutions were then diluted to a standard 
concentration of 1µg DNA/µl. 
 
 
 
 
 
                                                                                                                             
Experimental Methods 
 
 42  
 
3.2.1.4 Standard Polymerase chain reaction (PCR) 
DNA isolation by PCR fallowing protocol: 
Amount 
0.5µL 
2µL 
1µL 
0.4µL 
0.4µL 
20µL 
0.5-1µL 
Ingredient 
Template DNA(0-1µg/µl) 
Buffer 10X with MgSO4  
dntp mix (2mM) 
Forward primer (10µM) 
Reverse primer (10µM) 
ddH2O 
DNA polymerase 
Table.6 The PCR machine programming according to the manufacturer’s protocol 
3.2.1.5 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to analyzing DNA. The DNA was seen in the gel by 
addition of fluorescent dye ethidium bromide that binds strongly to DNA.   
In this study, 0.7 %-1% of agarose was used in agarose gels. 
Generally 1% gel shows good separation (resolution) of large DNA fragments (5-10kb).  1% 
agarose was prepared from 3.5g of agarose and 350ml of TAE (40mM Tris-acetate (pH 8.0), 
1mM EDTA). Agarose was added into a flask containing 1xTAE. Then it was heated in a 
microwave until it was dissolved. The amount of water lost through boiling was 
supplemented. The flask was then cooled to 50°C in a water bath. The agar was 
simultaneously poured into the electrophoresis chamber. The gel was allowed to polymerize. 
The gel chamber was filled with 1xTAE buffer. The wells of the gel were loaded with 10µl of 
required samples and DNA marker. The voltage was set to 80 V and the gel was run for 
approximately 60min. In order to observe the DNA under a UV lamp at 260nm, the gel was 
stained with ethidium bromide solution (10mM Tris-HCl, 1mM EDTA, 1mg/ml ethidium 
bromide) for 10min and then washed with water to remove excess ethidium bromide. The 
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bands were then photographed with a ChemiDoc XRS Scanner and and the QuantitiyOne 
4.6.5 software. 
3.2.2   Transfection of HEK 293T cells and HeLa cells 
The Effectene transfection reagent (Qiagen) was used to transfect HEK293T or HeLa cells 
according to the manufacturer’s protocol. HEK29T or HeLa cells were seeded on the 10 cm 
dishes at a density of 6*105. After cells reaching 80% confluence, cells were splitted from 10 
cm dish to 6 cm dish. Then the cells were incubated at 37 oC and 5% CO2. After 24h, the 
medium was replaced with the transfection mixture. The transfection mixture was prepared 
according to protocol bellow and incubated for 10min at RT. 
 
 
 
 
 
 
Table 7: Transfection mixture 
24h after transfection, the medium was replaced with normal medium or by yohimbine 
(100nM) containing DMEM medium for α2A-AR transfected cells for 3 to 4h. Yohimbine 
was used to prevent potential serum-derived stimulation of α2A-AR. Transfected cells were 
splitted on cover slips. Before splitting cover slips were coated with poly-Lysine (see below) 
to increase adherence of the cells. Cells were incubated overnight with 37oC to allow the 
expression of construct. The next day cells were measured. 
The following protocol was used for coating of glass cover slips: 
Before coating, cover slips were dipped in to ethanol for 30min and then washed with PBS 
buffer to remove residual ethanol and then placed into 6-well plates. 200µl of poly-L-lysine 
(0.1mg/ml) was dropped onto each cover slip and left for 30min. The solution was then 
removed, and cover slips were washed with 1ml PBS buffer. 
3.2.3 Fluorescence microscopy 
Ingredient 
DNA 
buffer 
enhancer 
effectene 
 
 Quantity 
1µl 
150µl 
8µl 
10µl 
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3.2.3.1 FRET-based microscopy in intact cells 
After 40-50h transfection, FRET measurements of transiently transfected intact cells were 
essentially performed at room temperature by using an inverted microscope (Axiovert 100, 
Zeiss) equipped with a PLAN/Apo N 60x/1.45 oil objective lens (Olympus), a SPOT Pursuit 
CCD-Camera (Spot Imaging solutions) and two cooled precisExcite LED illumination system 
(Visitron Systems, Germany). The following filters (Chroma, Semrock) were used for the 
FRET measurements: CFP-Excitation filter 436/20, YFP-Excitation filter 500/20,  a long pass 
beam splitter to collect combined fluorescence of CFP and YFP  458LP (Semrock), 500LP a 
beam splitter to separate CFP and YFP emission,  HC 470/24 (CFP) and HC 525/39 (YFP) 
emission filters (all from Semrock). CFP and YFP images were recorded by using a CCD 
camera. Cells were mounted on a home-built perfusion chamber and continuously super 
fused with Tyrode solution or agonist containing solution (see section 3.2.9.1) using 
pressurized perfusion system (Ala-VC³-8SP, Ala Scientific Instruments). CFP and YFP 
emissions were collected every 2s and illumination time was set to 30ms. Fluorescence of the 
cell was recorded at 440nm (F440 for CFP) and 500 nm (F500 for YFP). Later it was corrected 
for background subtraction, resulting in FYFP and FCFP. In order to determine FRET, 
additionally FYFP was corrected for bleed-through (see section 3.2.3.3). The FYFP/FCFP ratio 
was calculated with the Visitron software, and represented in the intensity modulated display 
mode. For the quantification, the FYFP and FCFP intensities were exported to Excel software. 
The FYFP/CFP values before stimulation were averaged and used as a reference. The ratio of 
raw FYFP/FCFP value to the reference value was defined as the normalized FYFP/FCFP. 
3.2.3.2 Correction factors  
To calculate the FRET ratio, two correction factors must first be determined: bleed through 
and false excitation. The tail of CFP emission spectrally overlaps with the emission of the 
YFP. Depending on the chosen emission filters, a part of the CFP emission is collected 
together with the YFP emission. This is called the bleed-through of the CFP into the YFP 
emission. Furthermore, EYFP is excited during FRET measurement with ECFP excitation. 
This phenomenon is called YFP-false excitation. In this study, these correction factors were 
used to subtract from original FRET traces. 
3.2.3.3 CFP fluorescence bleed-through  
In order to determine CFP-bleed through, HEK293T cells were transiently transfected with 
only one CFP-containing plasmid. CFP expressed cells were measured on the microscope as 
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described in (section 3.3.3.1). F470 and F525 were recorded and corrected for background 
fluorescence. The correction factor for bleed-through was calculated by dividing F525 by F470. 
The resulting correction factor for bleed-through was 0.3335 (Protocol was adapted from 
Milde et al., 2013). 
3.2.3.4 False excitation of YFP 
In order to determine YFP-false excitation, HEK293T cells are transfected with a YFP-
containing plasmid. The fluorescence FYFP is recorded for excitation at 440±12 nm (filter 
setting 458LP) and 500±10 nm (filter setting CFP/YFP dual band filter). Both F-values were 
corrected for background fluorescence and F525 (440) is divided by F525 (500). The YFP false 
excitation value was 0.371 (Protocol was adapted from Milde et al., 2013). 
3.2.4 cAMP measurements 
To measure receptor-mediated cAMP levels, cells were transfected with wild-type receptor 
together with a FRET-based cAMP sensor, AC-wt. Then the cAMP levels were measured by 
FRET imaging as described previously (3.2.3.1).  
3.2.5 Translocation measurements  
Translocation experiments of transiently transfected HEK293T cells were performed about 
40-50 h after transfection at room temperature by using an inverted  confocal microscope (IX 
71, Olympus) equipped with a 100x oil immersion objective (UPlanSApo 100x/1.40 oil, 
Olympus), a CCD camera (EM-CCD Digital Camera, Hamamatsu) and a confocal imaging 
system (VT-HAWK, VisiTech international). The following filters were used for the 
translocation experiments. T495lpxr, ET 470/40x and ET 535/30m (Chroma). Cells were 
mounted in a home-built perfusion chamber and continuously superfused with Tyrode 
solution or agonist-containing solution (see section 3.2.9.1) using a pressurized perfusion 
system (Ala-VC³-8SP, Ala Scientific Instruments). Samples were then illuminated with 491 nm 
laser (VisiTech International). By using the software VoxCell Scan (VisiTech international) 
the fluorescence recordings were measured. For translocation experiments, AKT-PH-YFP 
transfected cells were directly excited at 491 nm, and YFP fluorescence was recorded at 
2 Hz. YFP emission images were collected every 5s with 250ms integration time. To analyze 
membrane translocation AKT-YFP two ROIs (region of interest) were defined one ROI in the 
cell cytosol (Fcytosol) and another ROI in the whole cell (Ftotal). Then the quotient Fcytosol/Ftotal 
was calculated. The 20 time points of Fcytosol/Ftotal values before the first stimulation were 
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averaged and used as a reference. The ratio of raw Fcytosol/Ftotal to the reference value was 
defined as the normalized (Fcytosol/Ftotal). 
3.2.6 Electrophysiology 
These experiments were performed by Dr. Hariharan Subramanian in Dr. Viacheslav O. 
Nikolaev lab in a collaborative effort. 
To monitor real-time cAMP levels in cardiac myocytes, atrial myocytes were isolated from 
the adult transgenic mice expressing cAMP FRET sensor (Epac1-camps) (Calebiro et al., 
2009) by a Langendorff perfusion apparatus. FRET measurements of Epac1-camps expressed 
in isolated atrial myocytes were performed at room temperature using the Ti-S inverted 
fluorescence microscope (Nikon) with an x60 oil immersion objective (CFI P-Apo 60x 
Lambda, Nikon) and CCD camera (ORCA-03G, Hamamatsu Photonics). Cells were mounted 
in Ibidi perfusion chambers and superfused with Tyrode soultion or agonist containing 
solution (see section 3.2.10.1). CFP excitation was achieved by using a 440nm CoolLED 
light source with an ET436/30M excitation filter and a DCLP455 dichroic mirror. For CFP 
and YFP FRET recordings, it was used the 05-EM filter set containing the 505 cdxr dichroic 
mirror plus ET 480/30M and ET 535/40M emission filter for CFP and YFP, respectively. 
Ratiometric FRET measurements were performed by simultaneously recording YFP/CFP 
fluorescence via DV2 Dual view beam splitter (Photometrics). Cells were excited for 10-
50ms once every 5 s. FYFP was corrected for direct excitation and bleed-through. FRET ratios 
were calculated as ratio of corrected YFP over CFP emissions (FYFP/FCFP). The ratio of 
FYFP/FCFP value to the baseline value was defined as the normalized (FYFP/FCFP).  
3.2.7 Total RNA extraction and Real-time PCR 
3.2.7.1 RNA preparation from HEK and HeLa cells 
HEK29T and HeLa cells were seeded on the 6 cm dish and transfected by using effectene 
transfection reagent. After reaching 80% confluence of the cells, cells were washed with ice-
cold PBS and then snap frozen at -80oC.  
3.2.7.2 RNA extraction and reverse transcription. 
Total RNA was isolated by using RNeasy mini kit (Qiagen) according to the manufacturer’s 
protocol, 30µl of RNase-free water was used to elute the RNA (provided in the kit). Isolated 
RNA samples were treated with TURBO DNase (Ambion) to remove DNA contamination. 
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The concentration of RNA was determined by using a nano photometer. Reverse 
transcription was done by iScript cDNA Synthesis Kit (Bio-Rad) according to the 
manufacturer protocol. The reaction mix was incubated on thermal cycler. The program for 
thermal cycler was 25oC for 5min, 42oC for 30min, and 85oC for 5min. After incubation, the 
cDNA was kept at 4oC. 
3.2.7.3 Real-time PCR 
After reverse transcription, real-time PCR was performed by using an iTaqTM Universal 
SYBER Green Supermix (Bio-Rad). The reaction mix was prepared according to the 
manufacturer protocol (Bi-Rad). The reactions were carried out in optical 96 well reaction 
PCR plates (Applied Biosystems) in StepOnePlus Real-Time PCR system (Applied 
Biosystems). The PCR program used was at 50oC for 2min, 95oC for 10 min, 95oC for 15sec 
and 60oC for 1 min with 40 repetitions. Samples were measured in triplicates. qRT-PCR data 
were processed and analyzed by 2-∆∆CT method, where CT values were first normalized to 
internal control (GAPDH) and then to the mean of the control sample (defined as 1). Primers 
used are shown in Table 8. Transcripts of AC5 and AC6 were specific for human.  
 
  #     Type                        Primer sequence                                                    Gene 
  1     Forward               5′-GCACAGGAGCACAACATCAG-3′ 
         Reverse                5′-CACGATGAGCACGTAGATGAG-3′                         AC5 
  2     Forward               5′-CAAACAATGAGGGTGTCGAGT-3′ 
         Reverse                5′-TGCTACCAATCGTCTTGATCTT-3′                AC6 
  3     Forward               5′-CCAGGCGCCCAATACG-3′ 
         Reverse                5′-CCACATCGCTCAGACACCAT-3′                   GAPDH 
Table 8: Primer sequences of ACs (AC5 and AC6). GAPDH served as internal control 
 
3.2.8 Ligand binding assay 
The radioactive ligand binding experiments were performed by Alexandra Birk in a 
collaborative effort.  
To determine receptor expression levels, cell membranes were prepared from HEK293T 
cells. HEK29T cells were seeded on 6 cm dish and transfected by using effectene transfection 
reagent. After reaching 80% confluence of cells, cells were washed once with warm PBS. 
Cells were then detached by using buffer 1 (see section 3.2.9.12) with EDTA and 1 tablet of 
protease inhibitor cocktail (Roche, Penzberg, Germany) Cell membranes were centrifuged at 
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14,000 rpm for 1h at 4oC. Discard the supernatant and cell pellets were washed with buffer 2 
(see section 3.2.9.13) and resuspended with the same buffer. Cells were then sonified. 
Membrane receptor-specific binding was determined by incubating saturating concentrations 
(700nM) of [3H]-clonidine hydrochloride (Perkin Elmer, USA) overnight at 4oC and 10µM 
yohimbine hydrochloride was used to determine nonspecific binding. GF/C glass fiber filters 
were used to separate bound and unbound ligand by vacuum filtration. Filters were washed 
four times with ice-cold buffer 3 (see section 3.2.9.14) and counted in a liquid scintillation 
counter (Packard 1600 TR).  
3.2.9 Data analysis and statistics 
Agonist-induced FRET-signal amplitudes and background signal intensities were obtained 
with the software. The obtained intensity values were exported and analyzed with Excel 2007 
(Microsoft Corporation). All agonist-induced FRET-signals were corrected for 
photobleaching by subtracting background intensities. The corrected agonist-induced FRET-
signals were normalized to the baseline value. Unless stated otherwise we compared Epac-
based FRET signals to baseline referred as ∆(FYFP/FCFP norm.). In most of the figures (except 
Fig. 8 and 9), time points ‘a’ and ‘b’ are indicated.  The indicated time point (b) was defined 
as the time when the maximally-evoked FRET-amplitude after withdrawal of Gi agonist was 
reached and the indicated time point (a) was defined as the time of before exposure of 
agonist. 
Confocal images were evaluated in Image J and all statistics were obtained using GraphPad 
Prism and OriginPro by ANOVA with Bonferroni test.   
3.2.9 Buffers 
In our study most of the buffers were prepared in ultra-filtered water (Ultra clear UV plus 
Reinstwassersystem; SG Wasseraufbereitung, Barsbuttel, Germany) 
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3.2.9.1        Tyrode solution 
 
3.2.9.2        5x BSA solution 
 
 
 
 
 
 
 
3.2.9.3        LB-broth 
 
 
 
 
 
 
   Ingredient 
   NaCl 
   KCl 
   HEPES 
   CaCl2 
   MgCl2 
   ddH2O 
Amount 
137mM 
5.4mM 
10mM 
2mM 
1mM 
adjust to final volume of 1L 
                      adjust pH to 7.4 
Ingredient 
BSA 
ddH2O 
    Amount 
   10mM 
   adjust to final volume 
                    adjust pH 7.4 
   Ingredient 
   Peptone 
   Yeast extract 
   NaCl 
   ddH2O 
 Amount 
 1.0% 
 0.5% 
 1% 
adjust to finalvolume 
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3.2.9.4    LB-medium 
 
 
3.2.9.5     Transformation and storage buffer (TSB) 
Ingredient 
PEG 3000 
DMSO 
MgCl2 
LB-broth 
Amount 
10% 
5% 
20mM 
adjust to final volume of 50mL 
                
3.2.9.6     5x KCM buffer (for transformation of competent bacteria) 
Ingredient 
KCl 
CaCl2 
MgCl2 
H2O 
Amount 
500mM 
150mM 
250mM 
adjust to final volume of 50mL 
 
 
 
 
 
 
 
Ingredient 
Agar 
LB-broth 
Amount 
       1.5% 
       adjust to final volume 
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3.2.9.7         0.5 M EDTA 
 
 
 
3.2.9.8         50x TRIS buffer 
   Ingredient 
   Tris base 
   EDTA (0.5 M, pH8) 
  Glacial aceteic acid 
   H2O 
Amount 
242g 
10mL 
57.1mL 
adjust to final volume of 1L 
3.2.9.9        10x Agarose gel loading buffer  
        Ingredient 
        glycerol 
        EDTA 
        Tris 
        Orange G 
        H2O 
Amount 
40 % 
10mM 
10mM 
0.25% 
adjust to final volume  
 
 
 
Ingredient 
EDTA 
NaOH 
H2O 
Amount 
35g 
-4g 
adjust to final volume of 200mL 
                   adjust pH to 8.0 with NaOH 
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3.2.9.10      50x TAE buffer (agarose gel electrophoresis) 
 
3.2.9.12      Buffer 1 (for ligand binding assay) 
 
                Ingredient                                      Amount 
 NaCl                                              50mM 
                 NaH2PO4                                                          20mM 
                 MgCl2                                              3mM 
                 EDTA                                            1mM 
     ddH2O                                           adjust to final volume of 10mL 
                              adjust pH to 7.4 
                Ingredient 
               Tris (base) 
               Galcial acetic acid 
               EDTA (0.5 M)(see above) 
               ddH2O 
                      Amount 
                      242g 
                      57.1mL 
                      10mL 
           adjust to final volume of 1L 
 
 
3.2.9.11     Tris Lysis buffer 
                          Ingredient 
                  Tris 
                  EDTA 
                  Protease inhibitor mix  
         (Ultra Mini EDTA-free tablet)    
                  ddH2O                                                                                                                             
                Amount 
               20mM 
               2mM 
               1 Tablet 
              adjust to final  volume of 50mL 
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3.2.9.13      Buffer 2 (for ligand binding assay) 
  
                Ingredient                                      Amount 
                 NaCl                                               100mM 
                 Tris Base                                        20mM 
                 ddH2O                                            adjust to final volume of 50mL 
                                              adjust pH to 7. 
 
3.2.9.14       Buffer 3 (for ligand binding assay) 
                Ingredient                                      Amount 
                Tris Base                                         50mM 
                ddH2O                                             adjust to final volume of 1L 
                                                 adjust pH to 7.4
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4. Results 
4.1. Muscarinic receptor-induced cAMP rebound stimulation in HEK293T cells. 
The cAMP rebound stimulation was observed previously after termination of Gi-coupled 
receptor agonist in AC5 and Epac1-camps expressing HEK293T cells (Milde et al., 2013). 
Therefore we first reproduced the well described cAMP rebound phenomenon after 
withdrawal of Gi-coupled receptor agonist in intact cells. In order to reproduce these rebound 
effects, HEK293T cells were transiently transfected with 0.25µg of FRET-based cAMP 
biosensor (Epac1-camps), 0.3µg of AC5-wt and 0.1µg of M2-R. About 24h after transfection, 
cAMP levels were measured by FRET imaging.  
 
Figure 8: Acetylcholine induced cAMP rebound stimulation in HEK293T cells. 
A, Representative FRET-based recording of Gi-induced cAMP alterations was measured in HEK293T 
cells transiently expressing the cAMP biosensor Epac1-camps, M2-receptor and AC5. Fluorescence of 
the biosensor expressing cells was excited at 436±15nm, and emissions of cyan fluorescent protein 
(CFP) (470±24nm) and yellow fluorescent protein (YFP) (525±39nm) were detected using ratiometric 
imaging. Cells were exposed to isoprenaline (Iso) for 3 min then acetylcholine (ACh) for 3 min as 
indicated by black bars. Top, FRET ratio FYFP/FCFP, Bottom, corresponding CFP and YFP emissions.  
B, Pseudo-colored images of changes in FRET response (YFP/CFP) of M2-R expressing HEK293T 
cells were taken at the indicated time points in Fig. A. Representative calibration bar indicates 
FYFP/FCFP. C, Quantification of iso (3nM)-evoked FRET changes as in A, calculated as FYFP/FCFP 
(norm.). Data are plotted for 3nM Iso prior to ACh (indicated with a in A), during costimulation with 
ACh (b) and after withdrawal of ACh (rebound stimulation indicated with c).  
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In order to see cAMP rebound responses, we first stimulated endogenous β2-adrenergic 
receptors using isoprenaline (Iso) and then treated the cells simultaneously for a short time 
with a acetylcholine (ACh) concentration to account for the huge number of spare receptors 
expected for heterologously expressed Gαi coupled receptors. Upon stimulation of 
endogenous β-receptors with sub-threshold concentrations of Iso (3nM), cAMP 
concentrations increased to a submaximal level (indicated as a in Fig. 8A), as reflected by a 
decrease in FRET. This rise of cAMP was inhibited to baseline by the addition of 0.3nM ACh 
(indicated as b in Fig. 8A). The concentration of ACh was chosen based on the EC50 of the 
Gi/AC5-interaction studies (Milde et al., 2013). However, subsequent washout of ACh 
resulted in a rapid reversal of the inhibitory effect, leading to an increase in the cAMP 
concentration (defined as rebound response) (indicated as c in Fig. 8A). This increased cAMP 
concentration was substantially higher than that observed in the presence of Iso before 
exposure to ACh (c versus b in Figure 8A), and it was close to a maximally stimulating 
concentrations of Iso (10µM) alone. The rebound induced a decrease in Epac1-camps FRET 
of 10.2±1.4% compared to 6.1±1.6% (comparing a to c in Fig. 9). In principle, the use of 
Epac1-camps should allow an absolute quantification of cAMP concentrations in intact cells. 
It was attempted to translate changes in FRET ratio measured in HEK cells into cAMP 
concentrations by establishing a concentration-response curve for changes in Epac1-camps 
FRET measured in vitro. The calibration procedure was described in Nikolaev et al., 2004. 
Based on the dynamic range of Epac1-camps, it was estimated that the ACh rebound 
increased the cAMP concentration from 0.9 by 3.1µM.  
4.2 Muscarinic receptor-induced cAMP rebound stimulation in cardiac myocytes. 
Several previous reports showed muscarinic receptor-induced cAMP rebound stimulation 
after withdrawal of agonist in cardiac myocytes (Wang & Lipsius, 1995; Belevych et al., 
2001). In order to observe a similar cAMP rebound phenomenon in cardiac myocytes, atrial 
myocytes were isolated from transgenic mice expressing the cAMP biosensor Epac1-camps 
(Calebiro et al., 2009), and cAMP concentrations were measured by FRET. The cAMP 
rebound stimulation experiments in cardiac myocytes were performed in collaboration with 
the group of Viacheslav O. Nikolaev. M2-R, β2-AR, and ACs are predominantly expressed in 
cardiac tissues (Dhein et al., 2001; Defer et al., 2000). Upon exposure to sub-threshold 
concentrations of the β-adrenergic receptor agonist Iso (3nM), increased but submaximal 
cAMP concentrations were observed as indicated by a decrease of the FRET signal (shown as 
a in Fig. 9A). Subsequent addition of 10µM of the muscarinic agonist ACh for 2 min 
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antagonized this response as indicated by increase in the FRET signal (b in Fig.9A). 
Furthermore, washout of ACh resulted in a rapid reversal of its inhibitory effect as indicated 
by a drop of the FRET signal significantly below the values reached prior to the exposure of 
ACh (c versus b in Figure 9A), indicating a robust increase in the cAMP concentration which 
represents the well documented cAMP rebound phenomenon (Wang & Lipsius, 1995). The 
underlying mechanism for this muscarinic receptor-induced cAMP rebound response was not 
clear. 
 
Figure 9: Acetylcholine induced cAMP rebound stimulation in adult atrial myocytes isolated 
from murine hearts. 
A, Representative FRET recording of cAMP was measured in single freshly isolated atrial cells from 
mice transgenically expressing the cAMP biosensor Epac1-camps. Fluorescence of the biosensor-
expressing atrial cells was excited at 436±15nm, and emissions of cyan fluorescent protein (CFP) 
(480±15nm) and yellow fluorescent protein (YFP) (535±20nm) were detected using ratiometric 
imaging. Cells were exposed to Iso and followed by ACh as indicated by black bars. Top, FRET ratio 
FYFP/FCFP, bottom, corresponding CFP and YFP emissions. The emission ratio (top, black trace) of 
FYFP (corrected for bleed-through of CFP, bottom, yellow trace) over FCFP (bottom, blue trace) was 
normalized to its initial value and plotted over the time course of the experiment. B, Pseudo-colored 
images of changes in FRET response (YFP/CFP) of a mouse atrial myocytes were taken from at the 
indicated time points in Fig. A. Calibration bar indicates FYFP/FCFP. C, Quantification of Iso (3nM)-
evoked FRET changes as in A was calculated as FYFP/FCFP (norm.) and plotted for 3nM Iso prior to 
ACh (shown with a in A), during costimulation with ACh (b) and after withdrawal of ACh (rebound 
stimulation shown with c).  
However, other groups speculated that two possible signaling mechanisms involved in 
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Gβγ facilitation of Gαs-stimulated AC4 and possibly AC7 (Belevych et al., 2001, Bett et al., 
2001). 
4.3 Muscarinic receptor-induced cAMP rebound stimulation is specific for AC5 and 
AC6 in HEK293T cells. 
We first asked whether the Gαs-stimulated AC5/6 signaling pathway is involved in 
muscarinic receptor-induced cAMP rebound stimulation. In order to investigate AC5/6 
involvement, Epac1-camps and M2-R were expressed in HEK293 cells together with or 
without AC5. Cells transfected with AC5 showed cAMP rebound stimulation (red trace) after 
termination of ACh. However, cells transfected with empty vector (pcDNA3) instead of AC5 
showed significantly lower muscarinic-induced cAMP rebound stimulation (black trace). 
 
Figure 10: Acetylcholine induced cAMP rebound responses in AC5 expressing HEK293T cells. 
Representative traces of FRET recordings of muscarinic receptor-induced cAMP rebound responses 
were measured in HEK293T cells transfected with Epac1-camps together with M2-R with or without 
AC5-wt. Cells were subjected to the indicated agonist exposure protocol in order to elicit cAMP 
rebound responses. A, Average traces were obtained from 8-10 single FRET recordings from cells 
that were transfected with M2-R and AC5 (red and blue) or M2-R and empty pcDNA3 (black). Only 
cells expressing AC5 produced rebound stimulation as reflected by a decline in the Epac1-camps-
FRET ratio after withdrawal of ACh (red versus black, time interval indicated with b). Cells 
expressing AC5 and M2-R produced a higher FRET signal upon exposure to only Iso but not ACh 
(blue trace). B, Experimental data derived from A were quantified with respect to Iso-mediated 
alterations of FYFP/FCFP (norm.) after withdrawal of ACh (FYFP/FCFP at time point b - FYFP/FCFP at time 
point a). All results are plotted as mean±S.E.M.  
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Cells transfected with pcDNA3 showed slightly reduced β2-AR mediated cAMP production 
and weak inhibitory effects upon exposure to ACh, which reveals a dependency on AC5 for 
both the β2-AR mediated rise in cAMP and its M2-R mediated attenuation (Fig. 10). These 
results indicated that muscarinic receptor-induced cAMP rebound responses are likely AC5 
mediated. It was also suggested previously that AC6 might involved in muscarinic receptor-
induced cAMP rebound responses. Therefore, we next asked whether AC6 is involved in 
muscarinic-induced cAMP rebound stimulation. In order to test this, Epac1-camps and M2-R 
were transfected into HEK293T cells along with or without AC6-wt. Similar to cells 
transfected with cDNA for AC5, cells transfected with cDNA for AC6 but not cells 
transfected with empty pcDNA3 vector produced cAMP rebound stimulation after 
termination of ACh (Fig. 11), which revealed a dependency on AC5/6 for muscarinic 
receptor-induced cAMP rebound stimulation. These results support the hypothesis that 
muscarinic receptor-induced cAMP rebound effects were mediated by AC5/6.  
 
Figure 11: Acetylcholine induced cAMP rebound responses are mediated by AC6 in M2-R 
expressing HEK293T cells. 
A, Representative averaged FRET recordings showing alterations in cAMP induced by application 
and subsequent withdrawal of 0.3nM ACh in HEK293T cells transfected with Epac1-camps and M2-R 
with (black) or without (grey) AC6 as indicated (n=6-7). The FRET signal of Epac1-camps was 
normalized to initial values. B, Iso-evoked alterations in FRET of the experiments shown in A were 
quantified as (FYFP/FCFP norm. at time point b) - (FYFP/FCFP norm. at time point a). All results are plotted 
as mean±S.E.M.  
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In addition, cells expressing a different Gi-coupled receptor, the α2A-AR, also produced 
similar cAMP rebound responses in an AC5/6-dependent manner (Fig. 12) 
 
Figure 12: Norepinephrine induced cAMP rebound stimulation in α2A-AR expressing HEK293T 
cells.  
A, Depicted are averaged FRET recordings (n=7-8) measured from cells that were transfected with 
α2A-AR and AC5 (red and blue) or with α2A-AR and empty pcDNA3 (black). Only AC5-expressing 
cells produced rebound responses as reflected by the decline in Epac1-camps-FRET ratio after 
withdrawal of norepinephrine (NE) (red versus black, time interval indicated with b) indicating cAMP 
rebound response. AC5 and α2A-AR expressing cells only exposed to Iso, but not to NE (blue trace) 
exhibited a higher FRET signal at the time interval indicated with b. B, Experimental data derived 
from  A were quantified with respect to Iso-mediated alterations of FYFP/FCFP (norm.) after withdrawal 
of NE (FYFP/FCFP at time point b - FYFP/FCFP at time point a). All results are plotted as mean±S.E.M.  
Thus, heterologously expressed Gαi-coupled receptors produced cAMP rebound stimulation 
after withdrawal of agonist. We also determined (α2A-AR) expression levels by means of 
radioligand binding. The expression of α2A-AR was 11.0±0.9pmol/mg membrane protein, and 
no specific binding of [3H]-clonidine hydrochloride could be detected in untransfected 
control cells. 
Next we asked whether cAMP rebound stimulation can be attributed to specific β2-receptor. 
In order to test this, the dopamine D1 receptor (D1-R) was used. Dopamine (D1) receptors 
couple to Gαs- which stimulates ACs resulting in an increase in cAMP. We measured Gi-
induced cAMP responses in HEK293T cells which co-expressed the D1-R in combination 
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with the α2A-AR. Dopamine was used to activate the D1 receptor, which stimulates AC5 
resulting in an increase of cAMP via Gαs-, and NE was used to antagonize the dopamine 
response. A cAMP rebound response was produced after termination of NE superfusion. 
However, cAMP rebound responses were observed only in cells expressing AC5 (red trace) 
but not in cells transfected with empty vector instead of AC5 (black) (Fig. 13). By comparing 
Gi-induced cAMP rebound stimulation in cells expressing different G protein coupled 
receptors (α2A-AR, M2-R, and D1-R), it can be concluded that Gi-induced cAMP rebound 
responses are not receptor-specific.  
 
Figure 13: Dopamine induced cAMP rebound responses in D1-R expressing HEK293T cells.  
A, Averaged FRET recordings showing alterations in cAMP induced by application and subsequent 
withdrawal of 0.3nM NE was measured in HEK cells transfected with Epac1-camps, D1-R  and α2A-
AR with or without AC5 as indicated (n=6-7). The FRET signal of Epac1-camps was normalized to 
its initial value. FRET recordings derived from cells that were not treated with NE are shown in blue. 
B, Amplitudes of dopamine-evoked alterations in FRET of the experiments shown in A were 
quantified as (FYFP/FCFP norm. at time point b) - (FYFP/FCFP norm. at time point a) for all three 
conditions. All results are plotted as mean±S.E.M.  
4.4 AC5 and AC6 dependent Gi-induced cAMP rebound responses are PTX-sensitive.  
AC5 and AC6 isoforms are predominantly expressed in the heart and many cells and 
antagonize Gαs-stimulated cAMP responses by activating inhibitory Gi-proteins (Hartzell et 
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proteins (Gi/o) but also by physiological concentrations of Ca2+ (Dessauer et al., 1998; Murthy 
et al., 1998). In addition, Wang & Lipsius showed that ACh-induced rebound stimulation in 
atrial myocytes are attenuated by pertussis toxin (PTX) treatment (Wang & Lipsius, 1995). 
Therefore, it was tested whether PTX can inhibit the cAMP rebound responses. In order to 
test the effect of PTX, HEK293T cells transfected with Epac1-camps, AC5-wt and α2A-AR 
were pre-treated with pertussis toxin (30ng/ml) (an inhibitor of Gi/o) for 3 to 5 hours and the 
effect of the cAMP rebound investigated by FRET. As expected, PTX treated cells were 
effectively uncoupled from Gαi-proteins and also showed significantly attenuated cAMP 
rebound levels upon withdrawal of α2A-AR stimulation (Fig. 14). These results are consistent 
with earlier findings and further confirm that Gi-induced cAMP rebound effects are mediated 
by a mechanism involving PTX-sensitive Gi-proteins in addition to AC5/6. 
 
Figure 14: Gi-induced cAMP rebound responses were mediated by PTX-sensitive G proteins 
(Gi).  
Averaged FRET recordings of Gi-induced cAMP rebound responses were measured in HEK293T 
cells transfected with Epac1-camps together with M2-R and AC5-wt. A, Treatment of AC5 and α2A-
AR expressing cells with PTX (30ng/ml >4h, black) attenuated both the initial NE-induced decline in 
cAMP and the subsequent rebound response compared to untreated cells (red) (n=6-8). B, 
Experimental data derived from A were quantified with respect to Iso-mediated alterations of 
FYFP/FCFP (norm.) after withdrawal of NE (FYFP/FCFP at time point b - FYFP/FCFP at time point a). 
Results are plotted as mean±S.E.M. 
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The above results showed that the cAMP rebound responses were induced by PTX-sensitive 
Gi-proteins. Therefore, we next asked whether any specific Gi-proteins are mediating this 
rebound effect. In order to investigate this, HEK cells were transfected to overexpress Gαi1 or 
Gαi2 or Gαi3 together with Epac1-camps, α2-AR and AC5, and Gi-induced cAMP levels were 
measured. We observed no significant changes in Gαi-induced cAMP rebound stimulation in 
cells transfected with different Gαi-proteins (Gαi1, Gαi2 and Gαi3) compared to control 
conditions (red, blue and green versus black trace) (Fig. 15) indicating that Gi-induced cAMP 
rebound responses are not specific for  Gαi1, Gαi2 and Gαi3 proteins. 
 
Figure 15: cAMP rebound responses were observed independent of the Gαi-subtype 
A, Averaged FRET recordings showing Gi-mediated alterations in cAMP induced by application and 
subsequent withdrawal of 0.3nM NE  in HEK293T cells overexpressing Gαi1 or Gαi2 or Gαi3 together 
with Epac1-camps, α2-AR and AC5. The FRET signal of Epac1-camps was normalized to initial 
values. B, Iso-evoked alterations in FRET of the experiments shown in A were quantified as 
(FYFP/FCFP norm. at time point b) - (FYFP/FCFP norm. at time point a) for all four conditions. All results 
are plotted as mean±S.E.M. (n=5-6).  
4.5 Gi-induced cAMP rebound responses in HeLa cells 
The experiments described so far showed that heterologously expressed AC5 and AC6 
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investigate this, HeLa cells were chosen and transfected to express Epac1-camps and M2-R 
together with or without AC5-wt. Cells transfected with AC5 produced cAMP rebound 
stimulation after termination of muscarinic receptor agonist ACh (black trace). On the other 
hand, cells expressing empty vector (pcDNA3) produced significantly lower cAMP levels 
(gray trace) (Fig. 16). In addition, the onset of the Gi-inhibitory effect after application of the 
muscarinic agonist ACh on cAMP concentrations was more rapid in HeLa cells compared to 
HEK293T cells. It is likely that this rapid Gi-inhibitory effect is due to high 
phosphodiesterase activity in HeLa cells which degrade cAMP very rapidly. 
 
 
Figure 16: Acetylcholine induced a cAMP rebound responses in HeLa cells. 
Gi-induced cAMP rebound responses were measured in HeLa cells transfected with Epac1-camps 
together with M2-R and AC5-wt. A, Averaged FRET recordings showing alterations in cAMP 
induced by application and subsequent withdrawal of 0.3nM ACh in HeLa cells (n=6-7). The FRET 
signal of Epac1-camps was normalized to its initial value. B, Experimental data derived from A were 
quantified with respect to Iso-mediated alterations of FYFP/FCFP (norm.) after withdrawal of ACh 
(FYFP/FCFP at time point b - FYFP/FCFP at time point a). All results are plotted as mean±S.E.M.  
From these experiments, it is concluded that Gi-induced cAMP rebound responses are similar 
irrespective of different receptors or cell types.  
AC5/6 dependent Gi-induced cAMP rebound stimulation was measured in intact cells by 
using heterologous overexpression system. However, the AC5/6 protein expression levels 
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were not determined. Therefore, we next asked whether AC5/6 are overexpressed in intact 
cells or not. Due to a lack of suitable specific antibodies for AC5 and AC6, it was impossible 
to determine the expression of ACs on the protein level. Instead, AC5 and AC6 mRNA levels 
were measured in HEK and HeLa cells by qRT-PCR. Considering the transfection efficiency, 
(40-50% for HEK cells and 10-20% for HeLa cells) AC5 and AC6 mRNA were found to be 
at least eight-fold increased in AC-transfected cells compared to control cells (Fig. 17). 
 
                         
Figure 17: Relative mRNA expression levels were incresed in AC5 and AC6 transfected HEK 
and HeLa cells. 
A, HEK293T cells were transfected to express Epac1-camps and the α2A-AR together with ACs (AC5 
or AC6) or pcDNA3. The relative mRNA expression levels of AC5 or AC6 were measured by qRT-
PCR and normalized to the internal control (GAPDH) and are shown relative to control cells. Bar 
graphs represents the mean ± S.E.M from three independent transfections. B, Relative mRNA 
expression levels of AC5 and AC6 in HeLa cells. Representative data are relative to control cells. Bar 
graphs represent the mean±S.E.M from 2 independent transfections. 
4.6   Effects of PDE3 and PDE4 inhibition on Gi-induced cAMP rebound stimulation. 
The concentration of intracellular cAMP is not only dependent on cAMP generation by AC, 
but also on the action of cAMP-phosphodiesterases (Baillie & Houslay, 2005). However, it 
has been reported earlier that a PDE3-dependent NO-cGMP pathway is involved in the Gi-
induced cAMP rebound increase in atrial myocytes (Wang & Lipsius, 1995 and 1998). 
Therefore, it was tested whether PDE3 and PDE4 inhibitors have any effect on Gi-induced 
cAMP rebound responses in HEK cells. Before investigating this possible mechanism, it was 
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necessary to examine the effects of PDE inhibitors on cAMP levels. It is known that PDE3 
and PDE4 inhibitors generate cAMP via Gαs. In order to test the effects of PDE inhibition on 
cAMP levels, cells were transfected with Epac1-camps, AC5, and α2A-AR. Prior to the 
experiment, cells were pre-incubated with PDE3 or PDE4 inhibitors (cilostamide and 
rolipram, respectively). As expected, cells in which PDE3 or PDE4 had been inhibited 
produced higher cAMP levels upon Iso treatment compared to control conditions (Fig. 18).  
                                                                                              
Figure 18: PDE inhibition induced cAMP accumulation 
In order to explore the effectiveness of PDE inhibition in Epac1-camps expressing HEK293T cells we 
followed the time course of cAMP decline after withdrawal of 1µM Iso (as indicated) by means of 
FRET. Averaged data are shown for cells continuously exposed to 10µM of the indicated inhibitors 
(n=5-6). 
The above results showed a clear participation of PDE3 and PDE4 to cytoplasmic cAMP 
degradation upon β-adrenergic stimulation (Fig. 18). Therefore, it was decided to check the 
effects of these PDE inhibitors on Gi-induced cAMP rebound responses. To test this, 
HEK293T cells were transfected to express Epac1-camps, AC5, and α2A-AR. In order to 
avoid saturation of sensor upon treatment of PDE inhibitors, cells were pre-incubated with 
the inverse β-receptor agonist alprenolol for 20 to 30min. Treatment of these cells with 10µM 
cilostamide (a PDE 3 inhibitor) in combination with a submaximal concentration of Iso for 3 
min led to an increase of cAMP levels, and these increased cAMP levels were reduced to 
basal levels by addition of 0.3nM NE. Furthermore, subsequent washout of NE resulted in 
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cAMP rebound stimulation. However, the Gi-induced cAMP rebound stimulation was not 
attenuated in these cells (Fig. 19).  
 
                
Figure 19: PDE3 inhibition did not attenuate Gi-induced cAMP rebound stimulation. 
Exploring the effects of PDE3 inhibition on cAMP rebound stimulation was measured in HEK293T 
cells expressing Epac1-camps, AC5 and α2A-AR. A, Averaged FRET data showing that the cAMP 
rebound stimulation after withdrawal of NE-induced α2A-AR activation was not sensitive to inhibition 
of PDE3 with cilostamide. The FRET signal of Epac1-camps was normalized to initial values. B, 
Alterations in FRET of the experiments shown in A were quantified as (FYFP/FCFP norm. at time point 
b) -
 
(FYFP/FCFP norm. at time point a). All results are plotted as mean±S.E.M. (n=7-8). To avoid 
saturation of the sensor upon treatment of PDE3 inhibitor, cells were pre-incubated with the inverse β-
receptor agonist alprenolol for 20 to 30min. 
These results indicate that PDE3 inhibitor cilostamide did not affect Gi-induced cAMP 
rebound stimulation. These data are in line with earlier findings in ventricular myocytes that 
PDE3 inhibition failed to inhibit Gi-induced cAMP rebound stimulation (Belevych et al., 
2001). These results also indicate that PDE3-dependent NO-cGMP signaling does not 
represent a major mechanism for ACh-induced inhibition in cAMP rebound stimulation. In 
addition, very similar results were observed in the presence of the PDE4 inhibitor rolipram. 
Rolipram also did not affect Gi-induced cAMP rebound stimulation (Fig. 20). These results 
argue against a major contribution of PDEs in the generation of the Gi-induced cAMP 
rebound stimulation (Wang & Lipsius, 1995). Therefore, it was concluded that PDE3-
dependent NO-cGMP signaling pathway is not involved in Gi-induced cAMP rebound levels. 
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Figure 20: PDE4 inhibition did not attenuate Gi-induced cAMP rebound stimulation. 
Exploring the effects of PDE4 inhibition on cAMP rebound stimulation was measured in HEK293T 
cells expressing Epac1-camps, AC5 and α2A-AR. A, Averaged FRET data showing that the cAMP 
rebound stimulation after withdrawal of NE-induced α2A-AR activation was not sensitive to inhibition 
of PDE4 with rolipram. The FRET signal of Epac1-camps was normalized to initial values. B, 
Alterations in FRET of the experiments shown in A were quantified as (FYFP/FCFP norm. at time point 
b) -
 
(FYFP/FCFP norm. at time point a). All results are plotted as mean±S.E.M. (n=6-7). To avoid 
saturation of the sensor upon treatment with the PDE4 inhibitor, cells were pre-incubated with the 
inverse β-receptor agonist alprenolol for 20 to 30min.  
4.7 Gi-induced cAMP rebound responses are mediated via Gβγ  
As mentioned earlier, Gβγ facilitation of Gαs-stimulated AC4 and possibly AC7 could be 
another possible mechanism for Gi-induced cAMP rebound responses (Bett et al., 2002). So 
far, it was not demonstrated that AC7 is directly stimulated by Gβγ. Therefore, we first asked 
whether a Gβγ-dependent mechanism is involved in Gi-induced cAMP rebound stimulation. 
To test this mechanism, cells were transfected to express Epac1-camps, AC5, and α2A-AR. In 
order to check for the importance of Gβγ signaling, cells were pre-incubated with the Gβγ 
inhibitor gallein (which blocks all Gβγ-dependent signaling (Lehamann et al., 2008)) for 
40min and Gi-induced cAMP rebound responses were compared with control conditions. 
Intriguingly, application of gallein significantly attenuated the Gi-induced cAMP rebound 
stimulation (black trace) compared to the control condition (red trace). These data support the 
hypothesis that Gβγ-dependent mechanisms are involved in the Gi-induced cAMP rebound 
stimulation (Fig. 21). 
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Figure 21: Gi-induced cAMP rebound responses are mediated by Gβγ 
A, Epac1-camps based measurement of Gi-induced cAMP rebound stimulation was performed in 
HEK293T cells transfected with α2A-AR and AC5. Cells were pre-incubated with 1µM of the gallein 
(Gβγ inhibitor) or vehicle for 40min (n=6-8). The averaged data demonstrate a loss of the cAMP 
rebound response after withdrawal of NE in cells treated with gallein. B, Experimental data derived 
from A were quantified in respect to Iso-mediated alterations of FYFP/FCFP (norm.) after withdrawal of 
ACh (FYFP/FCFP at time point b - FYFP/FCFP at time point a). Results are plotted as mean±S.E.M.  
As a positive control of gallein, its effect on the interaction between PLCβ2 and Gβγ was 
measured. It was shown previously that Gβ1γ2 activates PLCβ2 (Wang et al., 1999). In order 
to study the interaction between PLCβ2 and Gβγ, cells were transfected to express PLCβ2-
Cerulean, YFP-tagged Gαq, M3-R, Gβ1 and Gγ2. Cells were then stimulated with ACh, 
resulting in activation of PLCβ2. However, application of gallein significantly abolished the 
interaction of Gβγ with PLCβ2 (Fig. 22).  
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Figure 22: Galleine effectively inhibitied the interaction between PLCβ and Gβγ  
Averaged FRET data showing inhibition of the interaction of PLCβ and Gβγ were measured in cells 
expressing PLCβ2-Cerulean, Gq-YFP, M3-R, Gβ1 and Gγ2. Cells were pre-incubated with 10µM 
gallein (Gβγ inhibitor) or vehicle for 40min (n=7-8). Cells were then stimulated with 10µM ACh 
leading to effective interaction of PLCβ with Gβγ. However, application of gallein significantly 
inhibited this interaction. Results are plotted as mean±S.E.M.  
In order to ensure that the Gi-induced cAMP rebound responses were specifically due to 
activation of Gβγ signaling, HEK cells were transfected to overexpress Gβγ together with 
Epac1-camps and AC5. By this treatment, we expected an enhancement of the Gi-induced 
rebound stimulation after termination of NE application. Surprisingly, cells overexpressing 
Gβγ exhibited inhibitory effects (black trace) on Gi-induced cAMP rebound levels compared 
to the control condition (red trace) indicating that Gβγ was not mediating Gi-induced cAMP 
rebound responses. Indeed, these data are conflicting with the results obtained with gallein. 
These conflicting results are remained an a open question and potential discrepancy is 
discussed in the discussion part. 
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Figure 23: Gβγ overexpression reduced the Gi-induced cAMP rebound stimulation in HEK 
cells. 
A, Averaged FRET recordings showing alterations in cAMP induced by application and subsequent 
withdrawal of 0.3nM NE were measured in HEK293T cells expressing Epac1-camps, α2A-AR and 
AC5 with or without overexpression of Gβγ. The FRET signal of Epac1-camps was normalized to 
initial values. B, Iso-evoked alterations in FRET of the experiments shown in A were quantified as 
(FYFP/FCFP norm. at time point b) - (FYFP/FCFP norm. at time point a). All results are plotted as 
mean±S.E.M. (n=10-11). 
Nevertheless, the experiments involving Gβγ inhibition by gallein suggested that a Gβγ-
dependent mechanism is involved in Gi-induced cAMP rebound stimulation. However, it was 
not clear if this cAMP rebound stimulation was due to Gβγ-mediated activation of AC4. 
Therefore, we next asked whether Gβγ-mediated activation of AC4 was involved in Gi-
induced cAMP rebound stimulation. In order to investigate this, cells were transfected to 
overexpress Epac1-camps and α2A-AR with or without AC4 and cAMP levels were 
measured. Intriguingly, cells expressing AC4 showed significantly reduced cAMP rebound 
stimulation. By comparing cAMP rebound responses in HEK cells that had been transfected 
with AC4, AC5 or AC6, only cells expressing AC5 and AC6 induced a cAMP rebound 
stimulation (Fig. 24). Functional expression of AC4 was indicated by a lack of Gi-mediated 
inhibition, and there was no cAMP rebound stimulation at all. However, the cAMP levels 
were significantly reduced in AC4-expressing cells suggesting that Gβγ-mediated stimulation 
0 100 200 300 400 500 600 700 800
0.84
0.88
0.92
0.96
1.00
AC5+Gβγ
AC5
Time(sec)
3nM Iso
0.3nM NE
F
/F
(n
o
rm
.)
Y
F
P
C
F
P
A
AC
5+
Gβ
γ
AC
5
-0.10
-0.05
0.00
a
b
B
Δ
(F
/F
n
o
rm
.)
Y
F
P
C
F
P
Results 
 
 71   
 
of AC4 is not involved in Gi-induced cAMP rebound stimulation, which argues against the 
hypothesis that Gi-induced cAMP rebound stimulation is induced by Gβγ-activated AC4. 
 
                       
Figure 24: Gi-induced cAMP rebound stimulation is not mediated by Gβγ-activated AC4  
A, Averaged FRET recordings showing Gi-induced cAMP rebound stimulation was measured in 
HEK293T cells overexpressing AC4, AC5 or AC6 together with Epac1-camps and α2-AR. Cells 
expressing AC5 (red trace) and AC6 (black line) produced Gi-induced cAMP rebound stimulation but 
not AC4 expression (blue line). The FRET signal of Epac1-camps was normalized to initial values 
and quantified. All results are plotted as mean±S.E.M. (n=7-8).  
It is not clear why Gβγ-activated AC4 produced lower cAMP levels than AC5-expressing 
cells but based on the results with gallein, one could conclude that Gβγ-dependent signaling 
is involved in Gi-induced cAMP rebound stimulation. Furthermore, it has been reported 
previously that Gβγ can conditionally stimulate AC5 in Sf9 cells (Katada et al., 1987). In 
order to address the question whether Gβγ-activated AC5 is mediating Gi-induced cAMP 
rebound stimulation, HEK cells were transfected with a mutant AC5 lacking amino acids 66-
137 which constitute the Gβγ binding site (AC5∆66-137) mutant together with Epac1-camps 
and measured Gi-induced cAMP levels. The AC5∆66-137 mutant showed significantly less 
FRET between AC5 and Gβγ interaction than full-length AC5 (Sadana et al., 2008).  
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Figure 25: Gi-induced cAMP rebound stimulation is not mediated by Gβγ-induced activation of 
AC5.  
A, Scheme illustrates full length AC5 and the βγ binding site deletion mutant AC5∆66-137. B, 
Averaged FRET recordings comparing Gi-induced cAMP rebound levels was measured in HEK293T 
cells expressing AC5∆66-137 or full length AC5 together with Epac1-camps and α2A-AR which were 
subsequently subjected to the cAMP rebound stimulation protocol. The FRET signal of Epac1-camps 
was normalized to initial values. C, Experimental data derived from A were quantified with respect to 
Iso-mediated alterations of FYFP/FCFP (norm.) after withdrawal of NE (FYFP/FCFP at time point b - 
FYFP/FCFP at time point a). All results are plotted as mean±S.E.M. (n=5-6). Fig. A is adapted from 
Sadana et al., 2011. 
Cells expressing full length AC5 produced cAMP rebound stimulation after termination of 
NE (Fig. 25 red trace). However, cells expressing the AC5∆66-137 mutant did not show 
attenuated Gi-induced cAMP rebound stimulation after termination of NE (Fig. 25 black 
trace). This suggests that the cAMP rebound stimulation is not mediated by direct Gβγ 
activation of AC5. These results argue against the hypothesis that a Gβγ-dependent AC 
mechanism is involved in Gi-induced cAMP rebound stimulation. Therefore, it can be 
concluded that Gβγ-facilitation of Gαs-stimulated AC4 is not a primary mechanism for Gi-
induced cAMP rebound responses despite the fact that Gβγ inhibition studies (Fig. 21) 
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revealed that a Gβγ-mediated signaling mechanism is involved in Gi-induced cAMP rebound 
stimulation. This Gi-induced cAMP rebound stimulation might be due to either an indirect 
Gβγ stimulation of adenylyl cyclases or an activation of different Gβγ-dependent 
mechanisms. For example, Gβγ-dependent stimulation of phospholipase C activity and 
subsequent activation of protein kinase C leads to activation of AC5/6 and thereby increases 
cAMP levels (Calpham & Neer, 1997). In addition to PKC, Gβγ also directly activates 
phosphoinositide-3 (PI3) kinase (Viard et al., 1999). Indeed, our previous gallein data also 
suggested that Gβγ-dependent PI3 kinase might be involved in cAMP rebound stimulation 
(Fig. 21) (Ukhanov et al., 2011). Therefore, the next aim was to identify which signaling 
cascade is responsible for Gi-induced cAMP rebound effects.   
4.8 Effects of PKA on Gi-induced cAMP rebound responses in HEK cells. 
It is known that cAMP-dependent protein kinase A (PKA) is activated by cAMP and 
regulates many physiological responses (Tasken et al., 2004). It was shown previously that a 
selective PKA inhibitor (H-89) diminished Gi-induced cAMP rebound stimulation via a 
cAMP-dependent PKA mechanism in atrial myocytes (Wang & Lipsius, 1995). Therefore, 
we decided to investigate whether PKA has any effect on Gi-induced cAMP rebound 
responses. In order to check PKA involvement, Epac1-camps, AC5, and α2A-AR expressing 
cells were pre-incubated with or without a specific PKA inhibitor (KT5720) for 30 min and 
the Gi-induced cAMP rebound responses were compared with control conditions. It has been 
shown previously that PKA inhibitor H-89 significantly attenuated β2-AR mediated cAMP 
levels (Penn et al., 1999),
 
therefore we chose a different PKA inhibitor (KT5720) to study 
PKA effects on Gi-induced cAMP rebound stimulation. Application of 1µM KT5720 did not 
affect Gi-induced cAMP rebound stimulation (Fig. 26 black trace). As a control, cells that had 
not been incubated with KT5720 produced cAMP rebound stimulation (Fig. 26 gray trace). 
This result argues against a role of PKA on Gi-induced cAMP rebound stimulation. From this 
observation, it can be concluded that Gi-induced rebound stimulation is not specifically 
mediated by PKA. 
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Figure 26: Protein kinase A inhibition did not attenuate Gi-induced cAMP rebound stimulation. 
A, Averaged FRET recordings showing alterations in cAMP induced by application and subsequent 
withdrawal of 0.3nM NE was measured in HEK cells transfected with Epac1-camps, α2A-AR and AC5 
(n=6-7). The FRET signal of Epac1-camps was normalized to initial values. Cells were pre-incubated 
with 1µM of the PKA-specific inhibitor KT5720 or vehicle for 30min prior to the experiment (n=6-8). 
B), Experimental data derived from A were quantified with respect to Iso-mediated alterations of 
FYFP/FCFP (norm.) after withdrawal of NE (FYFP/FCFP at time point b - FYFP/FCFP at time point a). 
Results are plotted as mean±S.E.M.  
To show that KT5720 indeed inhibited PKA, the PKA-specific FRET biosensor AKAR4 was 
used. AKAR4 consist of a phosphopeptide binding domain (FHA1), a consensus region of 
PKA substrates and sandwiched with donor fluorophore (cerulean) and an acceptor 
fluorophore (cp venus). When PKA is inactive, the donor and acceptor fluorophores are far 
apart, resulting in low FRET. Upon phosphorylation by PKA, the substrate region binds the 
FHA1, bringing the donor and acceptor fluorophores together and resulting in high FRET 
(Depry et al., 2011). Cells were stimulated with 1µM Iso which leads to activation of PKA. 
However, the application of 1µM of the PKA inhibitor KT5720 significantly inhibited PKA 
activation (Fig. 27). Under basal conditions, the AKAR4 sensor-expressing cells displayed 
higher PKA activity. Therefore, in order to avoid saturation of the sensor, cells were pre-
incubated with a lower concentration (50nM) of PKA inhibitor prior to the experiment. In 
addition, we next tested whether the cAMP rebound response was translated into PKA 
activity. 
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Figure 27: KT5720 effectively inhibited PKA activation. 
HEK293T cells were transfected with 1µg of PKA-specific FRET-based sensor AKAR4. To avoid 
saturation of the sensor, cells were pre incubated with a low (submaximal) concentration of KT5720 
(50nM) prior to the experiment. Cells were then stimulated with 1µM of Iso leading to activation of 
PKA. Application of 1µM KT5720 (PKA inhibitor) attenuated FRET increases (n=5). All results are 
plotted as mean±S.E.M 
To measure PKA activity, the PKA specific FRET biosensor AKAR4 was used. In order to 
measure PKA activity, cells were transfected to express AKAR4, AC5, and α2A-AR. As 
mentioned above, to avoid saturation of sensor, cells were pre-incubated with a lower 
concentration of KT5720 (50nM) which was present throughout the whole experiment. Cells 
expressing AC5 produced a PKA rebound stimulation upon washout of the α2A-AR agonist 
NE (black trace) (Fig. 28). Furthermore, the Gi-induced PKA rebound stimulation was 
significantly diminished in cells expressing empty vector (pcDNA3) instead of AC5 (gray 
trace) (Fig. 28) 
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Figure 28: Gi activation induced PKA rebound responses. 
A, Averaged FRET data are showing Gi-induced alterations in PKA activity induced by application 
and subsequent withdrawal of 0.3nM NE was measured in HEK cells transfected with PKA-specific 
sensor (AKAR4) and α2A-AR with or without AC5 (n=6-7). Rebound effects occurred in the cells 
which had been transfected with AC5. Cells not transfected with AC5 not produced rebound response. 
The FRET signal of AKAR4 was normalized to initial values. B, Quantification of Iso-evoked 
alterations in cAMP between indicated time points (b-a) of the experiment shown in A. All results are 
plotted as mean±S.E.M 
In addition, Gi-induced cAMP rebound levels were also measured by using another FRET-
based cAMP bio-sensor, based on the hyperpolarization-activated cyclic nucleotide-gated 
channel (HCN) (HCN2-camps). Cells were transfected with AC5 and α2A-AR and either 
Epac1-camps or HCN2-camps. As expected, cells expressing Epac1-camps produced cAMP 
rebound stimulation after termination of NE (red trace), whereas cells expressing HCN2-
camps also produced similar cAMP rebound stimulation upon NE washout (black trace) (Fig. 
29). There was no difference between cells expressing HCN2-camps or Epac1-camps (Fig. 
29), indicating that Gi-induced cAMP rebound responses are not specific for the Epac-based 
cAMP sensor.  
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Figure 29: Gi-induced a cAMP rebound stimulation in HCN2-camps expressed HEK cells. 
HEK293T cells were transfected with AC5, α2A-AR and either HCN2-camps or Epac1-camps. A, 
Averaged FRET data comparing Gi-induced cAMP levels between HCN2-camps and Epac1-camps-
expressing cells. B, Iso-evoked alterations in cAMP were quantified between indicated time points (b-
a) of the experiments shown in A. Results are plotted as mean±S.E.M.  
4.9. Effects of protein kinases on Gi-induced cAMP rebound stimulation in HEK cells 
As mentioned earlier, signaling via inhibitory G proteins leads to regulation of several 
different pathways, most of which are mediated via Gβγ subunits including PKC, PKG and 
PI3K (Calpharm & Neer et al., 1997; Viard et al., 1999). Therefore, we first asked whether 
major protein kinases (including PKC, PLC, and PKG) are involved in Gi-induced cAMP 
rebound responses. In order to test the involvement of protein kinases, cells were transfected 
to express Epac1-camps, AC5, and α2A-AR. Cells were then pre-incubated with or without 
the broad-spectrum protein kinase inhibitor staurosporine (which inhibits many kinases 
including PKA, PKC and PKG) for 30min and Gi-induced cAMP rebound responses were 
compared with control conditions. Treatment with 1µM staurosporine did not show any 
impact on Gi-induced cAMP rebound stimulation (black trace) compared to the control 
condition (gray trace) (Fig. 30). There was no difference in Gi-induced cAMP rebound 
stimulation between staurosporine-treated and control cells (Fig. 30). These results are 
consistent with earlier findings that PKC inhibition does not affect Gi-induced rebound 
stimulation of L-type Ca2+ currents in ventricular myocytes (Belevych et al., 2001). 
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Figure 30: Staurosporine did not affect Gi-induced cAMP rebound stimulation. 
HEK293T cells were transfected with α2A-AR, Epac1-camps and AC5. A, Averaged FRET recordings 
show Gi-induced cAMP rebound stimulation induced by application and subsequent withdrawal of 
0.3nM NE. Cells were pre-incubated with 1µM of the non-selective protein kinase inhibitor 
staurosporine or vehicle (n=8-10) for 30min prior to the experiment. B, Iso-evoked alterations in 
FRET subsequent to withdrawal of NE were quantified at indicated time points (b-a) of the 
experiments shown in A. Results are plotted as mean±S.E.M.  
To show that staurosporine treatment was effective, it was tested for its ability to inhibit PKC 
by using the PKC-specific FRET biosensor Eevee-PKC. Eevee-PKC consists of a 
phosphopeptide binding domain (FHA1), a consensus region of PKC substrates and 
sandwiched with donor fluorophore (YPet) and acceptor fluorophore (EYFP). When PKC is 
inactive, the donor and acceptor fluorophores are far apart, resulting in low FRET. Upon 
phosphorylation by PKC, the substrate region binds the phosphopeptide binding domain 
FHA1, bringing the donor and acceptor fluorophores together and resulting in high FRET 
(Komatsu et al., 2011). HEK293 cells were transfected with a plasmid encoding the Eevee-
PKC sensor. Cells were stimulated by applying 10µM of the PKC-specific activator TPA (or 
PMA) resulting in activation of PKC. However, 1µM staurosporine (PKC inhibitor) 
significantly inhibited TPA-mediated PKC activation (Fig. 31). From these experiments, it 
can be concluded that Gi-induced cAMP rebound stimulation is not mediated by PKA, PKC, 
PKG and other staurosporine sensitive kinases. 
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Figure 31: Staurosporine effectively inhibitied PKC activity. 
Averaged FRET data showing PKC inhibition were measured in cells expressing the PKC-based 
FRET-sensor Eevee-PKC. Cells were stimulated with 1µM TPA (PKC specific activator) leading to 
activation of PKC. However, pre-treatment with 1µM staurosporine (PKC inhibitor) attenuated the 
TPA response (n=5). Results are plotted as mean±S.E.M.  
4.10. Effects of PI3K on Gi-induced cAMP rebound stimulation in HEK cells.  
It is known that class 1B PI3Ks (also known as PI3Kγ) are activated via PTX-sensitive Gαi-
coupled GPCRs. This activation of PI3Kγ is linked to a direct association of its catalytic 
domain with βγ subunits of inhibitory G proteins (Gi) (Stoyanov et al., 1995; Viard et al., 
1999). However, our previous results also suggested that βγ dependent PI3K signaling is 
involved in cAMP rebound stimulation (Fig. 21). Therefore, it was decided to study the 
involvement of PI3K on Gi-induced cAMP rebound stimulation. In order to investigate the 
involvement of PI3K on cAMP rebound effects, cells expressing Epac1-camps, α2A-AR and 
AC5 were pre-incubated with 1µM of the PI3K-specific inhibitor wortmannin, and Gi-
induced cAMP rebound responses were compared with control conditions. Notably, 
application of 1µM wortmannin significantly reduced Gi-induced cAMP rebound responses 
(red traces) compared to the control conditions (black trace) (Fig. 32).  
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Figure 32: AC5-dependent Gi-induced cAMP rebound stimulation in HEK cells requires PI3K 
activation. 
A, Epac1-camps based measurements of cAMP rebound responses were performed in cells 
transfected with α2A-AR with or without AC5 as indicated. Cells were either pre-incubated with 1µM 
of the PI3K-specific inhibitor wortmannin or vehicle for 30min (n=10-11). Averaged data 
demonstrate a loss of the cAMP rebound response after withdrawal of NE due to wortmannin in cells 
expressing AC5. B, Iso-evoked alterations in FYFP/FCFP (norm.) were quantified and compared for the 
indicated conditions (b-a). Results are plotted as mean±S.E.M.  
The reduction of FRET decreased from 11.2±1.2% to 5.6±1.5%. Based on in vitro cAMP 
calibrations of Epac1-camps, it was estimated that wortmannin reduced the cAMP 
concentrations from 4.1µM to levels of about 0.7µM. Interestingly, exposure to wortmannin 
significantly reduced Gi-induced cAMP rebound stimulation only in cells expressing AC5. In 
cells expressing empty vector (pcDNA3, green trace) instead of AC5 wortmannin did not 
show any effect on cAMP rebound stimulation compared to the control condition (blue trace) 
(Fig. 32).  
Since AC6-expressing cells also produced cAMP rebound stimulation, we asked whether 
wortmannin had any effect on cAMP rebound stimulation. In order to investigate wortmannin 
effects on AC6, cells were transfected with Epac1-camps, α2A-AR and with or without AC6 
and tested for Gi-induced regulation of  cAMP levels.  
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Figure 33: AC6-dependent Gi-induced cAMP rebound stimulation  in HEK cells requires PI3K 
activation. 
A, Epac1-camps-based measurements of cAMP rebound stimulation was performed in cells 
transfected with α2A-AR with or without AC6 as indicated. Cells were either pre-incubated with 1µM 
of the PI3K-specific inhibitor wortmannin or vehicle for 30min (n=6-7). Averaged data demonstrate a 
loss of cAMP rebound response after withdrawal of NE due to wortmannin treatment. B, Iso-evoked 
alterations in FRET subsequent to withdrawal of NE were quantified at indicated time points (b-a) of 
the experiments shown in A. Results are plotted as mean±S.E.M.  
In order to test for wortmannin effects on AC6, cells were pre-incubated with wortmannin for 
30min and Gi-induced cAMP rebound responses were compared with control conditions. 
Notably, application of 1µM wortmannin significantly diminished Gi-induced cAMP rebound 
stimulation (black trace) compared to control conditions (red trace) (Fig. 33). Reduction of 
FRET decreased from 11.8±0.92% to 0.72±1.3%. Based on in vitro cAMP calibrations of 
Epac1-camps, it was estimated that wortmannin reduced the cAMP concentrations from 
4.3µM to 0.74µM. These data suggest that a Gβγ-dependent PI3K pathway is involved in Gi-
induced cAMP rebound stimulation of AC5/6-expressing cells. 
An interesting observation shown in Fig. 32 and 33 was that exposure to wortmannin had a 
tendency to lower β2-AR mediated rise in cAMP levels in cells expressing AC5/6. However, 
wortmannin did not show any effect on β2-AR mediated rice in cAMP levels in cells 
expressing empty vector (pcDNA3) (Fig. 31). These data indicate that PI3Ks regulate ACs 
either directly or indirectly. To further confirm the effects of wortmannin on β2-AR mediated 
increase in cAMP levels, cells were transfected to express AC4, AC5 or AC6 together with 
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Epac1-camps. Exposure to 1µM wortmannin significantly lowered β2-AR mediated increase 
in cAMP levels only in cells expressing AC5 and AC6 (Fig. 34 B-C). Indeed, wortmannin did 
not reduce β2-AR mediated increase in cAMP levels in cells expressing AC4; it rather 
showed a tendency to higher cAMP production in response to the β2-AR agonist Iso (Fig. 34 
A). These results further confirm that PI3K is regulating ACs. However, it is not clear 
whether PI3 kinases are directly or indirectly regulating ACs.  
 
Figure 34: Activation of AC5 and AC6 is sensitive to wortmannin.  
A, Epac1-camps expressing cells were subjected to FRET-based recording of Gαs-induced cAMP 
levels illustrating the effect of 3nM Iso on cAMP levels. Cells were transfected with AC4, AC5 or 
AC6 as indicated and either treated with 1µM wortmannin or vehicle (n=7). B, Iso-evoked alterations 
in FRET induced by application of Iso were quantified as shown in A. Results are plotted as 
mean±S.E.M.  
As a positive control for wortmannin, PI3K inhibition was tested by using a PIP3 
translocation sensor (AKT-PH-YFP). This sensor specifically binds PIP3 at the plasma 
membrane through its PH domain. Wortmannin should reduce the cellular PIP3 content, 
thereby resulting in cytoplasmic localization of the AKT-PH-YFP sensor. 
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Figure 35: AKT-PH-YFP sensor displayed high basal PIP3 levels in HEK293T cells. 
Representative confocal images are AKT-PH-YFP transfected HEK293T cells. Cells were imaged 
before and after pre-treatement of 1µM wortmannin. In cells treated with vehicle the sensor was 
already located at the plasma membrane indicating high basal PIP3 levels. Cells were relocated to the 
cytosol in treatement with wortmannin. Scale bars 10µm. 
In order to further check for inhibition of receptor-mediated PI3K activity, cells were 
transfected to express AKT-PH-YFP. Cells were then pre-incubated with a lower 
concentration of wortmannin (50nM) in order to relocate AKT-PH-YFP to the cytosol (Fig. 
36 A); otherwise the sensor was already localized to the membrane indicating high basal PIP3 
levels (Fig. 35). Cells were then stimulated with platelet-derived growth factor (PDGFBB) 
which is well known to activate PI3K in many cells including HEK293T cells (Gao et al., 
2011) resulting in Akt translocation (translocation from the cytosol to the plasma membrane 
(Fig. 36A)) as reflected by decreasing the ratio of cytosolic AKT-PH-YFP relative to total 
cell fluorescence, which indicates increasing PIP3 levels (black trace) (Fig. 36B). However, 
application of 1µM wortmannin completely prevented Akt translocation to the plasma 
membrane (gray trace) (Fig 36B). 
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Figure 36: Wortmannin effectively  inhibitied the PI3K activation. 
HEK293T cells were expressed with PIP3-dependent translocation sensor (AKT-PH-YFP) and then 
cells were incubated with a low concentration of wortmannin (50nM) in order to allow for partial 
translocation of AKT-PH-YFP. A, Representative confocal images of AKT-PH-YFP localization in 
HEK293T cells prior and after exposure to 50ng/ml of the PI3K activator PDGFBB B, Averaged data 
(n=14-16) showing the time course of membrane translocation of AKT-PH-YFP in response to 
PDGF-R stimulation and inhibition in response to 1µM wortmannin by plotting the fractional 
cytosolic YFP-staining. Due to movements of the cell during the experiment it was more reliable to 
measure cytosolic versus whole cell fluorescence compared to membrane staining. Scale bars 10µm. 
4.11. Effects of PIP3 on Gi-induced cAMP rebound stimulation in HEK cells. 
Activation of PI3K leads to the generation of PI(3,4,5)P3 and PI(3,4)P2. Therefore, we next 
asked which phosphoinositol species is involved in PI3K-dependent cAMP rebound 
responses. In order to study this, cells were transfected to overexpress the PIP3-specific 
phosphatase PTEN, which is known to dephosphorylate PIP3, thereby decreasing PIP3 levels 
(Maehama et al., 1998). Intriguingly, overexpression of PTEN significantly attenuated Gi-
induced cAMP rebound levels as reflected by a decrease in FRET ratio in cells expressing 
AC5. The FRET ratio was reduced by 12.1±0.93% to 7.8±1.4%. Based on Epac-camps1 
calibration curves it was estimated that the cAMP concentrations after NE withdrawal are 
reduced from 6.0µM to 1.0µM (Fig. 37). Similar to wortmannin, cells overexpressing PTEN 
also show lower β2-AR mediated increases in cAMP levels. These results indicate that the 
generation of PIP3 is required for cAMP rebound responses. 
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Figure 37: Overexpression of PTEN reduced Gi-induced cAMP rebound stimulation in HEK 
cells. 
A, Averaged FRET data showing Gi-mediated alterations of cAMP responses induced by application 
and subsequent withdrawal of 0.3nM NE  were measured in cells expressing Epac1-camps, AC5, α2A-
AR and PTEN (grey) or empty vector (black). The data show a loss of the cAMP rebound response 
after withdrawal of NE due to PTEN overexpression (n=7-8). B, Iso-evoked alterations in FRET 
subsequent to withdrawal of NE were quantified at indicated time points (b-a) of the experiments 
shown in A. Results are plotted as mean±S.E.M.  
4.12. Effects of PI(3,4)P2 on Gi-induced cAMP rebound stimulation in HEK cells.  
As mentioned above, activation of PI3K also generates PI(3,4)P2. A major pathway leading to 
PI(3,4)P2 is the dephosphorylation of PI(3,4,5)P3 by the 5-phosphatase SHIP2 (Damen et al., 
1996). In order to test the involvement of PI(3,4)P2, cells expressing Epac1-camps, AC5 and 
α2A-AR were pre-incubated with or without the SHIP2 inhibitor AS 1949490 and Gi-induced 
cAMP rebound responses were compared. Application of 1µM AS 1949490 did not show any 
affect on Gi-induced cAMP rebound stimulation, which indicates that PI(3,4)P2 signaling is 
not involved in PI3K-dependent cAMP rebound responses (Fig. 38). Therefore, it is 
concluded that Gi-induced cAMP rebound responses are likely dependent on PIP3.  
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Figure 38: SHIP2 inhibition did not attenuate Gi-induced cAMP rebound stimulation in HEK 
cells. 
A, Averaged FRET data showing Gi-mediated alterations of cAMP rebound responses induced by 
application and subsequent withdrawal of 0.3nM NE was measured  in cells expressing Epac1-camps, 
AC5 and α2A-AR. Cells were pre-incubated with AS 1949490 (SHIP2 inhibitor) or vehicle (n=5-6). B, 
Iso-evoked FRET changes were quantified as alterations in FYFP/FCFP (norm.) and plotted for the 
indicated conditions (b-a). Results are plotted as means±S.E.M.  
4.13. Effects of AKT on Gi-induced cAMP rebound responses in HEK cells. 
Furthermore, it was tested whether important downstream effectors of PIP3 are involved in 
the generation of cAMP rebound responses. It is known that activation of PIP3 further 
stimulates downstream effectors such as PDK1 and Akt (Stoke et al., 1997; Klippel et al., 
1997). Therefore, we asked whether PIP3 downstream signaling is involved in the PI3K-
dependent cAMP rebound stimulation. In order to investigate this, the influence of Akt on Gi-
induced cAMP rebound stimulation was tested. To measure Akt effects, cells expressing 
Epac-1camps, AC5 and α2A-AR were pre-incubated with the Akt-specific inhibitor SH-5, and 
Gi-induced cAMP rebound responses were compared with control conditions. Application of 
10µM of SH-5 did not show any effect on Gi-induced cAMP rebound stimulation (gray trace) 
compared to control conditions (black trace) (Fig. 39). This result indicates that Akt and its 
downstream signaling are not involved in PI3K-dependent cAMP rebound responses. 
 
0 100 200 300 400 500 600 700 800
0.70
0.75
0.80
0.85
0.90
0.95
1.00
1.05
AC5+AS 1949490
AC5
Time (sec)
3nM Iso
0.3nM NE
a
b
AC
5+
AS
19
49
49
0
AC
5
-0.12
-0.08
-0.04
0.00
ns
A B
F
/F
(n
o
rm
.)
Y
F
P
C
F
P
Δ
(F
/F
n
o
rm
.)
Y
F
P
C
F
P
Results 
 
 87   
 
 
Figure 39: Akt inhibition did not affect Gi-induced cAMP rebound stimulation in HEK cells. 
A, Averaged FRET data showing Gi-mediated alterations of cAMP rebound responses induced by 
application and subsequent withdrawal of 0.3nM NE  was measured in cells expressing Epac1-camps, 
AC5 and α2A-AR. Cells were pre-incubated with SH-5 or vehicle (n=6-7). B, Experimental data 
derived from A were quantified with respect to Iso-mediated alterations of FYFP/FCFP (norm.) after 
withdrawal of NE (FYFP/FCFP at time point b - FYFP/FCFP at time point a). Results are plotted as 
mean±S.E.M.  
As a positive control for SH-5, we tested Akt inhibition by utilizing the PIP3-dependent 
translocation sensor (AKT-PH-YFP). To study Akt inhibition, cells expressing the AKT-
YFP-PH sensor were stimulated with platelet-derived growth factor (PDGFBB) resulting in 
Akt translocation as indicated by increase in PIP3 levels (black trace). However, application 
of 10µM Akt specific inhibitor SH-5 significantly attenuated Akt translocation as indicated 
by reduction of PIP3 levels (gray trace) (Fig. 40). In addition, the data obtained with the non-
selective kinase inhibitor staurosporine and PTEN (which also inhibits PDK1) already 
indicate that PDK1 is not involved in Gi-induced cAMP rebound responses (Fig. 30). 
Therefore, based on these results it is concluded that PIP3 either directly or indirectly 
mediates Gi-induced cAMP rebound responses. 
 
                  
-0.12
-0.08
-0.04
0.00
ns
A B
AC
5+
SH
5
AC
5
0 100 200 300 400 500 600 700 800
0.80
0.84
0.88
0.92
0.96
1.00
AC5+SH-5
AC5
Time (sec)
3nM Iso
0.3nM NE
a
b
F
/F
(n
o
rm
.)
Y
F
P
C
F
P
Δ
(F
/F
n
o
rm
.)
Y
F
P
C
F
P
Results 
 
 88   
 
                  
Figure 40: SH-5 effectively inhibited Akt activation. 
Representative average data showing the SH5-mediated blockade of Akt translocation in HEK293T 
cells expressing a PIP3-dependent translocation sensor (AKT-PH-YFP). Prior to the experiment, cells 
were pre-incubated with low concentrations of wortmannin (50nM) in order to allow for partial 
translocation of AKT-PH-YFP. Cells were then stimulated with 50ng/ml of the PI3K-specific 
activator PDGFBB leading to translocation of Akt from cytosol to plasma membrane as determined 
by plotting the ratio of cytosolic AKT-PH-YFP relative to total cell fluorescence. However, 
application of 1µM SH-5 (Akt inhibitor) completely abolished PDGF-induced membrane targeting of 
AKT-PH-YFP (n=5).  
4.14. Gi-mediated PIP3 activation via Gβγ. 
The above data suggested that Gi-induced cAMP rebound stimulation leads to production of 
PIP3. It is known from the literature that activation of PTX-sensitive Gi-coupled GPCRs 
activates PI3Kγ. This PI3Kγ activation has been linked to a direct association of its catalytic 
domain with the βγ subunits of G proteins (Stoyanov et al., 1995). Therefore, it was 
investigated whether the moderate Gi-coupled GPCR (α2A-AR) stimulation used in the cAMP 
rebound stimulation protocol described above actually leads to an increase of PIP3. To test 
this, we tested NE-mediated translocation of AKT-PH-YFP in HEK cells. As mentioned 
above in the absence of wortmannin, AKT-PH-YFP sensor is already completely localized to 
the plasma membrane. In order to achieve a cytosolic localization of the sensor in 
unstimulated cells, these experiments were carried out in the presence of a low concentration 
of wortmannin (50nM). Cells were then stimulated with NE, resulting in increasing PIP3 
levels (red trace) (Fig. 41 B) as reflected by translocation of the AKT-PH-YFP sensor from 
the cytosol to the plasma membrane (Fig. 41A).  
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Figure 41: α2A-AR receptor stimulation leads to elevation of PIP3 levels. 
A, Depicted are confocal images of HEK293T cells transfected with the PIP3 sensitive AKT-PH-YFP 
translocation sensor, AC5, and α2A-AR. Cells were pre-incubated with low concentrations of 
wortmannin (50nM) in order to relocate AKT-PH-YFP to the cytosol (left). Cells were then 
stimulated with 1µM NE leading to membrane targeting of AKT-PH-YFP (right). B, Depicted are 
averaged data for AKT-PH-YFP translocation to the plasma membrane by plotting the ratio of 
cytosolic AKT-PH-YFP relative to total cell fluorescence. To increase cytosolic AKT-PH-YFP 
localization cells were pre-incubated with 50nM wortmannin and stimulated with 1µM (red (n=10) 
and green (n=5) trace) or 0.3nM NE (blue traces (n=4)). Pretreatment with PTX (30ng/ml for >4h) 
abolished NE-induced membrane targeting of AKT-PH-YFP (green trace).  C, NE-induced alterations 
in YFP(cytosol)/YFP(whole cell) were quantified. Results are plotted as mean±S.E.M. Scale bar 10µm. 
These results clearly demonstrated that stimulation of the α2A-AR increases PIP3 levels. To 
demonstrate that this increase of PIP3 levels was mediated via PTX-sensitive proteins, cells 
were pre-incubated with PTX. As expected, the increase in PIP3 levels induced by activation 
of Gαi-coupled receptors was completely abolished by pre-treatment with PTX (green trace) 
(Fig. 41B-C). 
However, PI3Kγ is also directly activated by Gβγ (Stoyanov et al., 1995). Therefore, we 
asked whether Gβγ is involved in PI3K activation. In order to address this question, Gi-
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mediated PI3K activation was measured in HEK cells by using the AKT-PH-YFP 
translocation sensor. To study the involvement of Gβγ, cells were then pre-incubated with the 
Gβγ inhibitor gallein. Exposure to the α2A-AR agonist NE led to activation of PI3K. 
However, pre-incubation with 10µM gallein significantly reduced PI3K activation (Fig. 42). 
Based on these results, it can be concluded that PI3K is mediating Gi-induced cAMP rebound 
responses of AC5/6 expressing cells. 
 
Figure 42: Gi-activation leads to elevation of PIP3 levels via Gβγ. 
A, Averaged AKT-PH-YFP translocation data showing Gβγ-dependent alterations of PIP3 induced by 
application of 0.3nM NE in cells expressing AKT-PH-YFP. Cells were then stimulated with NE 
leading to activation of PIP3. However, subsequent preincubation and application of 10µM gallein 
(Gβγ inhibitor) significantly reduced NE-stimulated PIP3 activation. B, NE-induced alterations in 
YFP(cytosol)/YFP(whole cell) were quantified. Results are plotted as mean±S.E.M (n=3-5).  
4.15. Elevation of PIP3 potentiates Gαs-enhanced cAMP levels. 
The translocation assay revealed that Gi-induced cAMP rebound responses are mediated by 
PIP3 primarily in AC5/6-expressing cells. Therefore, the next aim was to determine whether 
elevations of PIP3 induced by other means than Gi protein activation would indeed sensitize 
AC5. In order to test this hypothesis, HEK293T cells expressing Epac1-camps, AC5, and 
α2A-AR were stimulated with platelet-derived growth factor (PDGFBB) (which is known to 
activate PI3K) and Gs-enhanced cAMP levels were measured. Stimulation of Epac1-camps 
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expressing cells with 50ng/ml PDGFBB significantly increased Gαs-enhanced cAMP levels 
(red trace) compared to a control condition (black trace) (Fig. 43A- B). 
                                        
Figure 43: Elevation of PIP3 causes sensitization of AC5 
A, Averaged FRET data showing effects of PDGF-receptor-mediated PIP3 production on Iso-
mediated cAMP responses were measured  in AC5-expressing cells (n=8-10). Cells expressing Epac1-
camps were (red) or were not (black) incubated with 50 ng/mL PDGFBB at the indicated time point 
during FRET imaging. B, PDGF-induced FRET changes after application of Iso of the 
experiments shown in A were quantified. Results are plotted as mean±S.E.M.  
These results suggest that ACs, specifically AC5/6 are regulated by PIP3. Furthermore, these 
results strongly support the hypothesis that PIP3 is mediating the Gi-induced cAMP rebound 
responses in AC5-expressing cells.  
4.16. Effects of PI3K on Gi-induced cAMP rebound responses in cardiac myocytes. 
Since the role of PIP3 for Gi-mediated cAMP rebound responses was so far only shown in a 
heterologous expression system, the next aim was to test whether the ACh-induced cAMP 
rebound phenomenon is also mediated by PIP3 in atrial cardiac myocytes 
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Figure 44: Wortmannin abolishes Gi-induced cAMP rebound responses in atrial myocytes.  
A, Isolated murine atrial myocytes from Epac1-camps expressing mice were pre-incubated with 1µM 
wortmannin or vehicle for 30min and subsequently subjected to the cAMP-rebound stimulation 
protocol as described in Fig.9A. Averaged FRET data demonstrate a loss of the cAMP rebound 
response after withdrawal of ACh in cells pre-treated with 1µM of wortmannin (n=6-9). B, 
Experimental data derived from A were quantified with respect to Iso-mediated alterations of 
FYFP/FCFP norm. after withdrawal of ACh (FYFP/FCFP at time point b - FYFP/FCFP at time point a). Results 
are plotted as mean±S.E.M.  
In order to test this, Epac1-camps expressing transgenic mouse atrial cells were pre-incubated 
with the PI3K inhibitor wortmannin and the Gi-induced cAMP rebound stimulation was 
measured. These experiments were performed in collaboration with Dr. Viaceslav O. 
Nikolaev work group. Notably, application of 1µM wortmannin significantly reduced the 
ACh-induced cAMP rebound levels (gray trace) compared to control conditions (black trace) 
(Fig. 44). This result suggests that also in murine atrial myocytes, cAMP rebound responses 
are largely dependent on PIP3-mediated adenylyl cyclase sensitization. Intriguingly, 
wortmannin had a tendency to lower AC activity in response to β-adrenergic receptor 
stimulation (Fig. 44), similar to what was observed in AC5-expressing HEK293T cells (Fig. 
32). 
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5. Discussion 
cAMP together with Ca2+ is the most prominent cytosolic second messenger in virtually all 
cells, which is generated by ACs through stimulatory G protein Gαs. cAMP regulates many 
different functions of the cell; consequently, dysfunction of cAMP regulation is involved in 
the pathology of many different diseases. Previously a cAMP rebound stimulation was 
identified after termination of Gαi-stimulation in cardiac myocytes as well HEK293T cells 
but the mechanism is still under debate (Ono et al., 1994; Wang et al., 1995; Belevych et al., 
2000; Milde et al., 2013). However, while studying the mechanism of this long known cAMP 
rebound phenomenon after termination of Gαi-stimulation in cardiac myocytes, we 
discovered a novel regulatory pathway that requires PI3 kinase activity and leads to 
sensitization of ACs, primarily AC5 and AC6 (Fig. 45). 
5.1 Gi-induced cAMP rebound responses are specific for AC5 and AC6 in HEK293T 
and HeLa cells. 
The Gi-induced cAMP rebound responses were originally described in cardiac myocytes. 
Similar to myocytes, the cAMP rebound responses were also described in HEK293T cells 
after termination of Gi stimulation by using real-time cAMP imaging with a FRET-based 
cAMP biosensor (Epac1-camps) (Milde et al., 2013). Primarily the cAMP rebound responses 
could be reproduced after withdrawal of Gi/o stimulation in two different heterologous 
overexpression systems (HEK293T and HeLa cells) (Fig. 8 and 16). These cAMP rebound 
effects were seen only when cells expressed AC5 and AC6, but not when expressing empty 
vector instead of AC5 or AC6 or in cells expressing AC4 (Fig. 10, 11 and 24), which 
supports the hypothesis that cAMP rebound responses are AC5/6 dependent (Belevych et al., 
2001; Bett et al., 2001). Indeed, native HEK293T and HeLa cells expressed AC5 and AC6 
only to a low extent, and the contribution of endogenous AC5/6 to functional cAMP 
production was minor. Due to lack of suitable AC5/6 specific antibodies for the detection of 
protein expression, we studied AC5/6 mRNA expression levels and found detectable amounts 
of AC5/6 in HEK and HeLa cells upon transfection (Fig. 17). During the investigation of Gi-
induced cAMP rebound responses, it was noted that cAMP rebound responses were not 
observed at maximally stimulating concentrations of Iso. These results are in line with earlier 
findings that cAMP rebound stimulation of the Cl- current was not observed if Gαs 
stimulation was fully activated by maximally stimulating concentrations of Iso (1µM) in 
guinea-pig ventrucular myocytes (Zakharov et al., 1997). These observations hinted towards 
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the rebound stimulation is due to facilitation of cAMP-dependent responses (Wang & 
Lipsius, 1995). 
Cells expressing a different Gi coupled receptor (α2A-AR) instead of the M2-R also produced 
similar cAMP rebound responses upon termination of treatment with the α2A-adrenergic 
receptor agonist NE (Fig. 12). cAMP rebound effects could also be elicited in cells 
expressing the Gαs-coupled dopamine D1 receptor in combination with the Gαi-coupled α2A-
AR. In these cells, a similar degree of cAMP rebound responses was observed upon 
termination of Gαi-activation compared to the β2-adrenergic receptor (Fig. 13). These results 
suggest that Gi-induced cAMP rebound responses are not receptor specific. In addition it was 
found that the Gi-induced cAMP rebound responses were sensitive to PTX. PTX-treated HEK 
cells were significantly inhibited in their ability to produce Gi-induced cAMP rebound 
responses (Fig. 14). These results are consistent with earlier findings that Gi-induced rebound 
stimulation of L-type Ca2+ current in atrial myocytes and cAMP-activated Cl--current in 
ventricular myocytes are attenuated by PTX treatment (Wang & Lipsus, 1995; Belevych et 
al., 1997). This observation indicated that cAMP rebound levels are mediated by PTX-
sensitive Gi/o proteins. Importantly, Gi-induced cAMP rebound responses were observed not 
only at the level of cAMP, but also by using AKAR4, a FRET reporter of PKA activity (Fig. 
28). In addition, Gi-induced cAMP rebound responses were also observed using HCN2-
camps (a different cAMP FRET-biosensor) (Fig. 29) 
However, the intracellular concentration of cAMP can be increased not only by stimulation of 
AC activity but also by an inhibition of PDE activity. It has been previously reported that the 
PDE3 dependent NO-cGMP pathway was involved in Gi-induced cAMP rebound increase in 
cat atrial myocytes (Wang et al., 1995; Wang et al., 1998). However, our results clearly argue 
against a major contribution of PDEs in cAMP rebound response: Inhibition of major PDE 
isoforms such as PDE3 and PDE4 did not attenuate the cAMP rebound response (Fig. 19 and 
20). These results are in line with previous studies that  PDE3-dependent NO-cGMP 
signaling is not involved in Gi-induced rebound cAMP effects in ventricular myocytes (Bett 
et al., 2002; Zakharov et al., 1997). In addition, inhibition of PKA is known to stimulate 
PDE4 activity but this had no detectable effect on the observed rebound responses. 
Furthermore, the fact that in a heterologous expression system the rebound response was 
completely absent when cAMP was produced via AC4 argues against a major role of PDEs in 
the generation of cAMP rebound stimulation. Therefore, it can be concluded that PDE3-
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dependent NO-cGMP signaling does not contribute to ACh-induced inhibition of cAMP 
rebound stimulation.  
By expressing different inhibitory Gαi proteins, we ruled out that cAMP rebound responses 
were restricted to certain Gi subtypes (Fig. 15). Furthermore, significantly lower cAMP 
rebound responses were observed when inhibiting Gβγ with galleine (Fig. 21), which 
suggests that a Gβγ-dependent mechanism is involved in cAMP rebound responses. These 
results are consistent with a proposed mechanism that Gβγ facilitation of Gαs-stimulated 
AC2/4 leads to cAMP rebound responses (Bett et al., 2001; Belevych et al., 2001). In 
addition, overexpression of G protein βγ subunits showed a significant reduction of Gi-
induced cAMP rebound response (Fig. 23). This argues against the results showing that the 
βγ inhibitor gallein significantly reduced cAMP rebound responses (Fig. 21). However, it is 
not clear why βγ overexpression had an inhibitory effect on Gi-induced cAMP rebound 
responses. One explanation could be that long term stimulation of PI3K with βγ could lead to 
desensitization of its production or it’s down stream signaling. However, this negative 
discrepancy still remains an open question. It was noted during the investigation of Gi-
induced cAMP rebound stimulation that Gi-induced cAMP rebound stimulation is long 
lasting (around 10-15 min) (data not shown). This observation is consistent with earlier 
findings that Gβγ-mediated stimulatory responses do not deactivate as quickly as inhibitory 
effects (Harvey et al., 2007). These data further strengthen the hypothesis that a Gβγ-
dependent signaling mechanism is involved in cAMP rebound responses. Surprisingly, Gi-
induced cAMP rebound responses were significantly reduced when cells expressed AC4 (Fig. 
24), which argues against the proposed mechanism that Gβγ-facilitated Gαs-stimulated AC4 
is involved in generation of the cAMP rebound responses. However, it has been reported 
previously that Gβγ conditionally activates AC5, resulting in an increase in cAMP levels. By 
using an AC5 mutant with the Gβγ binding site deleted, AC5∆66-137 (Sadana et al., 2007), 
we ruled out the possible involvement of Gβγ activation of AC5 in Gi-induced cAMP 
rebound responses. A similar degree of cAMP rebound responses was observed in cells 
expressing the AC5∆66-137 mutant compared to cells expressing full-length AC5 (Fig. 25). 
These results explain that the Gi-induced cAMP rebound responses are not directly mediated 
by Gβγ-activated ACs. 
Then the question arises, why do we see a significant reduction in cAMP rebound responses 
by Gβγ inhibition? There is a possible explanation for this. It could be that the cAMP 
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rebound stimulation may not actually directly involve Gβγ-dependent activation of ACs; 
perhaps another Gβγ-dependent mechanism is involved such as Gβγ-dependent stimulation of 
phospholipase C (PLC) activity and subsequent activation of protein kinase C (PKC) 
(Clapham & Neer, 1997) or a Gβγ-activated phosphoinositide 3 kinase-dependent signaling 
pathway (Vidar et al., 1998). Indeed, our Gβγ inhibition data (βγ inhibitor gallein 
significantly inhibits Gβγ activated PI3K) (Fig. 20) also hinted that Gβγ activated PI3K is 
involved in Gi-induced cAMP rebound stimulation (Ukhanov et al., 2011) 
5.2 PIP3 mediated Gi-induced cAMP rebound responses. 
Interestingly, the PI3K inhibitor wortmannin significantly lowered α2A-AR-induced cAMP 
rebound responses of AC 5/6 (Fig. 32, 33), which supports the hypothesis that Gβγ activated 
PI3K signaling was involved in Gi-induced cAMP rebound responses. These results are 
consistent with earlier findings, which reported that relaxin-mediated stimulation of cAMP 
was inhibited by PI3K inhibitors (LY294002 and wortmannin) in THP-1 cells (Nguyen et al., 
2003 and 2005). On the other hand, these findings are contrary to a previous report that 
cardiac-specific PI3Kγ-KO mice exhibit an increase in basal contractility (Patrucco et al., 
2004). However, the effect of PI3K inhibition on basal cAMP levels is not clear in most cell 
types or tissues, not even cells that vastly express AC5/6. Indeed, similar stimulatory effects 
were observed upon wortmannin treatment in the case of AC4-expressing cells in response to 
β2-adrenergic stimulation (Fig. 34). Furthermore, wortmannin had no effects on cells 
expressing empty vector instead of AC5 or AC6, suggesting that wortmannin effects were 
specific to AC5 or AC6 in HEK cells. In addition, using the well established PIP3 sensor 
AKT-PH-YFP, we were able to demonstrate that stimulation of α2A-adrenergic receptors 
under conditions very similar to those used to study rebound stimulation indeed led to an 
increase in PIP3 production (Fig. 41). The PIP3 levels required for AC5/6 specific stimulation 
are obviously higher than those needed for translocation of the AKT-PH domain. This could 
be deduced from the observation that overall PI3K activity in the absence of Gi/o stimulation 
had to be reduced in order to see Gi/o mediated translocation of the AKT-sensor (Fig. 36). In 
addition, the Gβγ inhibitor gallein completely abolished Gαi-mediated PI3K activity, which 
further confirmed PI3K signaling through Gβγ. However, these results are preliminary, and 
additional experiments are needed to substantiate them (Fig. 42). Furthermore, wortmannin 
pretreatment did not only fully inhibit cAMP rebound responses in AC5 expressing HEK 
cells but also completely abolished this response in adult mouse atrial myocytes (Fig. 44). 
These findings suggest that Gi-mediated cAMP rebound responses are mediated via a Gβγ-
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PI3K dependent pathway, both in cardiac myocytes and in heterologous expression systems. 
In atrial myocytes, AC5 and AC6 are predominantly expressed (Dhein et al., 2001; Defer et 
al., 2000; Mattick et al., 2007). This evidence for functional expression of AC5/6 in atrial 
myocytes comes from the the observation of robust inhibition in response to activation of 
inhibitory G protein (Gi), which indicates AC5 and AC6 regulation via PTX-sensitive Gi 
protein (Fig. 8A). Furthermore, termination of Gi activation leads to cAMP rebound 
responses. In mouse ventricular myocytes, we observed only very minor cAMP rebound 
responses after withdrwal of muscarinic receptor agonist. This low cAMP rebound responses 
might be due to a relatively lower expression of M2-R in ventricular myocytes compared to 
atrial myocytes and also suggest that basal cAMP levels might be higher in atrial myocytes 
(Deighton et al., 1990; Zakharov et al., 1997). Using both PTEN overexpression (which is a 
phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase, thereby lowering PIP3 levels 
(Maehama et al., 1998)) and SHIP2 inhibition (a phosphatidylinositol-3,4,5-trisphosphate 5-
phosphatase catalyzing the conversion of PIP3 into PI(3,4)P2 (Damen et al., 1996)), we 
identified PIP3 as the major phosphoinositol species that is involved in PI3K-dependent 
cAMP rebound responses (Fig. 37 and 38). However, our PTEN overexpression results are 
also contrary to a previous finding, which reported that functional impairment of PTEN leads 
to a decrease in cardiac contractility (Crackower et al., 2002). One explanation for this 
opposing effect could be that PI3Kγ not only regulates PIP3 levels but rather provides a 
scaffold for other important regulatory proteins including PDEs (Gregg et al., 2010).  
It has been previously reported that in THP-1 cells, relaxin stimulates PI3K activity, thereby 
enhancing AC activity resulting in increased cAMP levels. The authors further showed that 
these increased cAMP levels were mediated by PIP3 activated PDK1 downstream target, 
PKC ζ (Nguyen et al., 2005). However, our PTEN, staurosporine and KT5270 (even though 
this compound is sold as a PKA inhibitor, it also inhibits PDK1) data indicated already that 
PDK1 and its downstream targets are not involved in Gi-induced cAMP rebound responses 
(Fig. 26 and 30). Furthermore, Akt-specific inhibitors also failed to attenuate the Gi-induced 
cAMP rebound stimulation (Fig. 39). Therefore, a possible involvement of PIP3 downstream 
signaling on Gi-induced cAMP rebound effects could be ruled out. Instead, our data suggest 
that PIP3 itself either directly or indirectly mediates cAMP rebound responses.  
In addition, the broad-spectrum kinase inhibitor staurosporine failed to affect Gi-induced 
cAMP rebound responses (Fig. 30). These results indicate that Gi-induced cAMP rebound 
responses are not mediated by PKC, PKG and other staurosporine-sensitive kinases and also 
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rule out the possible Gβγ-dependent activation of PKC as a source for Gi-induced cAMP 
rebound responses. This finding is in line with earlier findings that a protein kinase C 
inhibitor did not block the cAMP rebound response of L-type Ca2+ currents induced by 
stimulation of muscarinic acetylcholine receptors in ventricular myocytes (Belevych et al., 
2001). 
In addition to PKC signaling, we ruled out a possible involvement of PKA signaling on the 
Gi-induced cAMP rebound response by PKA inhibition by showing that Gi-induced cAMP 
rebound responses were not affected by the PKA inhibitor KT5720 (Fig. 26).             
 
Figure 45: Proposed PIP3 pathway which is responsible for Gi-induced cAMP rebound 
stimulation.  
This finding seems to be contradictory to previous findings that a selective PKA inhibitor 
diminished the cAMP rebound responses which led to the claim that cAMP rebound 
responses are mediated via a G protein/adenylate cyclase/cAMP-dependent PKA signaling 
pathway in atrial myocytes (Wang & Lipsius, 1995). 
Importantly, exposure to wortmannin significantly lowered β-adrenergic enhanced cAMP 
levels only in cells expressing AC5 and AC6. Indeed, wortmannin did not reduce β2-
adrenergic enhanced cAMP levels in cells transfected with AC4; there was rather a tendency 
towards faster cAMP production in response to Iso (Fig. 34). These findings led us to 
conclude that PIP3 regulates primarily AC5 and AC6. This conclusion is strengthened by the 
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observation that the activation of PI3K in a Gi-independent manner through PDGF receptor 
stimulation also resulted in a stimulation of AC5 (Fig. 43).  
Due to the general importance of PI3K signaling in various tissues and cell types, we predict 
that PIP3 dependent AC regulation represents an important novel regulatory mechanism to 
fine tune cAMP homeostasis in cells. However, this study did not investigate whether PIP3 
has a direct effect on the level of adenylyl cyclases or whether any unidentified PIP3-
dependent regulatory proteins will indirectly mediate this effect. The next step should be to 
investigate these uncovered questions in the future. 
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5.4. Concluding remarks 
This work reported mechanisms underlying the well described cAMP rebound phenomenon 
after withdrawal of muscarinic stimulation in atrial myocytes by real-time cAMP imaging 
using the FRET-based cAMP biosensor Epac1-camps. By means of the heterologous 
expression system, we identified that muscarinic receptor-induced cAMP rebound responses 
were mediated via PTX-sensitive/AC5/6 dependent signaling and identified the involvement 
of the Gi-mediated PI3K pathway. Our results led us to conclude that AC5/6 but not AC4 is 
under the control of a novel PIP3 dependent regulation. These results could provide the 
mechanism underlying long known physiological phenomena such as postvagal tachycardia 
and arrhythmogenic mechanisms in the heart. Due to the general importance of PI3K 
signaling and broad expression of AC5/6 in various tissues and cell types we predict that PIP3 
dependent AC regulation represents an important novel regulatory mechanism to fine-tune 
cAMP homeostasis in cells. Future studies have to reveal whether PIP3 regulates AC5/6 
activity by direct interaction with the cyclase or exert its function via interaction with 
unknown AC-regulating proteins.  
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5.5. Key findings 
In this present study, three major findings were discovered in receptor-mediated regulation of 
cAMP levels 
• A PTX-sensitive AC5/6-dependent pathway underlies the Gi-induced cAMP rebound 
stimulation in intact cells. 
• This pathway is initiated via Gβγ-mediated activation of PI3K both in mouse atrial 
myocytes as well in HEK293T cells. 
• Elevation of PIP3 enhances AC5/6 activity and leads to pronounced physiologically 
relevant alterations of cytosolic cAMP levels.  
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6. Summary 
A wide variety of signaling substances such as hormones, neurotransmitters, odorants and 
chemokines control intracellular signaling by regulating the production of the second 
messenger cAMP. By activating Epac, PKA and cyclic nucleotide-gated ion channels, the 
production of cAMP alters a wide range of biological processes including cell division and 
metabolism. A number of GPCRs controls intracellular cAMP levels via stimulatory or 
inhibitory G proteins via adenylyl cyclases. The function of the broadly expressed AC5 and 
AC6 is enhanced by stimulatory (Gαs) or attenuated by inhibitory (Gαi) G proteins. 
Mechanistically both inhibition and stimulation is mediated via a direct protein-protein 
interaction. In addition to this direct regulation, several previous studies reported a cAMP 
rebound stimulation after withdrawal of Gi stimulation in cardiac myocytes for which the 
mechanism is debated (Hartzell, 1988; Wang & Lipsius, 1995). A similar cAMP rebound 
response was observed previously in our lab after termination of α2A-AR adrenergic receptor 
activation in HEK293T cells (Markus et al., 2013). The present study was aimed at 
investigating mechanisms underlying Gi-induced cAMP rebound effects. 
Many genetically encoded biosensors have been developed based on fluorescence resonance 
energy transfer (FRET) to visualize the spatiotemporal dynamics of various intracellular 
signals including second messengers. FRET-based cAMP biosensor (Epac1-camps) as well 
as heterologous overexpression system was used to investigate the mechanisms underlying 
Gi-mediated cAMP rebound stimulation in cardiac myocytes and also in heterologous 
expression system. When studying the mechanism of the long-known phenomenon of cAMP 
rebound stimulation after withdrawal of Gi stimulation in cardiac myocytes, we observed a 
PTX-sensitive/Gi-mediated/ adenylyl cyclase (type 5/6)/ cAMP-dependent pathway for this 
cAMP rebound stimulation.  
In addition, we observed that inhibition of Gβγ by gallein led to an attenuation of the AC5-
mediated cAMP rebound response, although, overexpression of AC4 did not produce 
additional cAMP stimulation. This implies that different Gβγ-mediated signaling pathways 
may exist. Interestingly, we observed that PI3K inhibitor attenuates AC5/6-dependent cAMP 
rebound effects. This indicated that Gi-mediated cAMP rebound response was mediated via 
the PI3K-dependent pathway. Indeed, overexpression of PIP3-specific phosphatase PTEN 
confirmed that PIP3 itself either directly or indirectly mediated Gi-dependent cAMP rebound 
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responses. Additionally, inhibition of PIP2-specific phosphatase SHIP and downstream events 
of PIP3-dependent regulation of Akt further confirm the influence of PIP3 on cAMP rebound 
levels. Indeed, surpassing Gi-mediated PI3K activation through PDGF-receptor stimulation 
strengthens this pathway. In addition, we confirmed that inhibition of PI3K also prevented 
cAMP rebound response after withdrawal of ACh in atrial myocytes. We suppose that the 
novel PIP3 dependent regulation of AC5/6 might represent a missing mechanism that explains 
physiological phenomena such as post vagal tachycardia. 
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7. Zusammenfassung 
Eine große Bandbreite von Signalmolekülen _ darunter Hormone, Neurotransmitter, 
Geruchsstoffe und Chemokine _ kontrollieren intrazelluläre Signale durch die Regulation des 
sog. zweiten Botenstoffs cAMP. Die Produktion von cAMP beeinflusst verschiedenste 
biologische Prozesse wie die Zellteilung und Stoffwechsel. Dies geschieht unter anderem 
durch die Aktivierung von Epac, PKA und cyclisch Nukleotid-gesteuerte Ionenkanäle. Eine 
Reihe von GPCR kontrolliert das intrazelluläre cAMP-Niveau mittels des Einflusses von 
stimulatorischen oder inhibitorischen G-Proteinen auf die Adenylylcyclasen. Die Aktivität 
der weit verbreiteten AC5 und AC6 wird durch stimulatorische G-Proteine (Gαs) erhöht, 
während sie durch inhibitorische G-Proteine (Gαi) verringert wird. Mechanistisch werden 
Inhibition und Stimulation durch direkte Protein/Protein-Interaktionen vermittelt. Zusätzlich 
zu dieser direkten Regulation wurde in anderen vorangegangenen Studien eine cAMP-
Rebound-Stimulation beschrieben. Diese trat in Kardiomyocyten auf, sobald die Aktivierung 
von Gi-Proteinen beendet wurde. Der zugrundeliegende Mechanismus ist umstritten 
(Hartzell, 1988; Wang et al., 1995). Ein ähnliches cAMP-Rebound-Verhalten wurde auch 
bereits in unserem Labor in HEK293T-Zellen beobachtet, nachdem die Stimulation α2A-
adrenerger Rezeptoren beendet wurde (Milde et al., 2013). Daher zielte die vorliegende 
Arbeit auf die Untersuchung des zugrundeliegenden Mechanismus dieses Gi-Protein-
induzierten cAMP-Rebound-Effekts. 
Es wurden viele genetisch kodierte Biosensoren entwickelt, die auf dem Förster/Fluoreszenz-
Resonanzenergietransfer (FRET) beruhen und mit denen die zeitliche und räumliche 
Dynamik von verschiedenen intrazellulären Signalen, einschließlich denen der zweiten 
Botenstoffe, sichtbar gemacht werden konnte. Der FRET-basierte cAMP-Biosensor Epac1-
camps wurde zusammen mit heterologen Überexpressionsmodellen benutzt, um den 
Mechanismus der Gi-Protein-vermittelten cAMP-Rebound-Stimulation in Kardiomyocyten 
und anderen lebenden Zellen zu untersuchen. Während der Untersuchung dieses 
wohlbekannten cAMP-Rebound-Phänomens beobachteten wir einen PTX-empfindlichen, 
Gi-Protein-vermittelten Typ5/6-Adenylylcyclase/cAMP-abhängigen Signalweg. 
Zusätzlich dazu stellten wir fest, dass die Inhibition von Gβγ-Untereinheiten durch Gallein zu 
einer Verringerung der AC5-vermittelten cAMP-Rebound-Antwort führte, während die 
Überexpression von AC4 keine zusätzliche Stimulation von cAMP bewirkte. Dies legt nahe, 
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dass verschiedene Gβγ-vermittelte Signalwege existieren. Bemerkenswerterweise 
beobachteten wir auch, dass, PI3K den AC5/6-abhängigen cAMP-Rebound-Effekt 
abschwächte. Dies deutete darauf hin, dass die Gi-vermittelte cAMP-Rebound-Antwort einem 
PI3K-abhängigen Signalweg unterliegt. Tatsächlich bestätigte die Überexpression der PIP3-
spezifischen Phosphatase PTEN, dass PIP3 selbst, entweder direkt oder indirekt, die Gi-
abhängige cAMP-Rebound-Antwort vermittelt. Der Einfluss von PIP3 auf die cAMP-
Rebound-Niveaus wurde zusätzlich durch die Inhibition der PIP2-spezifischen Phosphatase 
SHIP und weiterer Vorgänge unterhalb der PIP3-abhängigen Regulation von Akt bestätigt. 
Außerdem konnte der Signalweg verstärkt werden, wenn die Gi-abhängige PI3K-Aktivierung 
durch die Stimulation des PDGF-Rezeptors umgangen wurde. Zusätzlich dazu konnten wir 
bestätigen, dass auch in atrialen Myocyten die Inhibierung der PI3K die Ausbildung der 
cAMP-Rebound-Antwort verhinderte, nachdem Acetylcholin entfernt wurde. Wir vermuten, 
dass diese neu beschriebene PIP3-abhängige Regulation der AC5/6 jenen unbekannten 
Mechanismus darstellt, der physiologischen Phänomenen wie der post-vagalen Tachikardie 
zu Grunde liegt. 
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